PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 24 June 1999 (24.06.99)	
International application No. PCT/CA98/01059	**Applicant's or agent's file reference** 1770-183PCT
International filing date (day/month/year) 12 November 1998 (12.11.98)	**Priority date** (day/month/year) 12 November 1997 (12.11.97)
Applicant SZYF, Moshe et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

07 June 1999 (07.06.99)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer S. Mafla
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

Form PCT/IB/331 (July 1992)

2692856

PATENT COOPERATION TREAT 09/554414

From the INTERNATIONAL BUREAU

PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:
CÔTÉ, France
Swabey Ogilvy Renault
Suite 1600
1981 McGill College Avenue
Montréal, Québec H3A 2Y3
CANADA

Date of mailing (day/month/year) 20 May 1999 (20.05.99)	
Applicant's or agent's file reference 1770-183PCT	**IMPORTANT NOTICE**
International application No. PCT/CA98/01059	**International filing date** (day/month/year) 12 November 1998 (12.11.98)
Priority date (day/month/year) 12 November 1997 (12.11.97)	
Applicant McGILL UNIVERSITY et al	

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
   AU,CN,EP,IL,JP,KP,KR,US

   In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:
   AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,CA,CH,CU,CZ,DE,DK,EA,EE,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MD,MG,MK,MN,MW,MX,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,UA,UG,UZ,VN,YU,ZW
   The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on
   20 May 1999 (20.05.99) under No. WO 99/24583

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, **a demand for international preliminary examination** must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the **national phase**, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Continuation of Form PCT/IB/308

09/554414

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

Date of mailing (day/month/year)	IMPORTANT NOTICE
20 May 1999 (20.05.99)	
Applicant's or agent's file reference	**International application No.**
1770-183PCT	PCT/CA98/01059

The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/52, 9/00, A61K 38/43, C07K 16/40, C12N 15/11, A61K 48/00, G01N 33/50

A1

(11) International Publication Number: WO 99/24583

(43) International Publication Date: 20 May 1999 (20.05.99)

(21) International Application Number: PCT/CA98/01059

(22) International Filing Date: 12 November 1998 (12.11.98)

(30) Priority Data:

2,220,805	12 November 1997 (12.11.97)	CA
2,230,991	11 May 1998 (11.05.98)	CA

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant *(for all designated States except US)*: McGILL UNIVERSITY [CA/CA]; 845 Sherbrooke Street West, Montréal, Québec H3A 2T5 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SZYF, Moshe [CA/CA]; 7522 Wavell, Côte Saint-Luc, Québec H4W 2L7 (CA). BHATTACHARYA, Sanjoy [IN/CA]; Apartment 1403, 2150 Mackay Street, Montréal, Québec H3G 2M2 (CA). RAMCHANDANI, Shyam [CA/CA]; 5843 Hillcrest Crescent, Niagara Falls, Ontario L2J 2A8 (CA).

(74) Agents: CÔTÉ, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(54) Title: DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF

(57) Abstract

The present invention relates to a DNA demethylase enzyme having about 40 KDa, and wherein said DNA demethylase enzyme is overexpressed in cancer cells and not in normal cells. The present invention also relates to the therapeutic and diagnostic uses of the DNA demethylase.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF

BACKGROUND OF THE INVENTION

(a) Field of the Invention

The invention relates to a novel enzyme, DNA demethylase, therapeutic and diagnostic uses thereof.

(b) Description of Prior Art

Many lines of evidence have established that modification of cytosine moieties residing in the dinucleotide sequence CpG in vertebrate genomes is involved in regulating a number of genome functions such as parental imprinting, X-inactivation, suppression of methylation of ectopic genes and differential gene expression (Szyf, M. (1996) Pharmacol. Ther. *70*, 1-37). DNA methylation performs its function of differentially marking genes because the distribution of methylated CpGs is tissue- and site- specific forming a pattern of methylation (Szyf, M. (1996) Pharmacol. Ther. *70*, 1-37). It is clear that the pattern of methylation is fashioned by a sequence of methylation and demethylation events (Brandeis, M. et al. (1993) Bioassays *15*, 709-713) during development and is maintained in the fully differentiated cell (Razin, A. et al. (1980) Science *210*, 604-610). While it was originally suggested that DNA demethylation is accomplished by a passive loss of methyl groups during replication (Razin, A. et al. (1980) Science *210*, 604-610), it is now clear that an active process of demethylation occurs in embryonal cells (Frank, D. et al. (1991) Nature *351*, 239-241), in differentiating cell lines (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA *83*, 2827-2831; Szyf, M. et al. (1985) Proc. Natl. Acad. Sci. USA *82*, 8090-8094) and in response to estrogen treatment (Saluz, H.P. et al. (1986) Proc. Natl. Acad. Sci. USA *83*, 7167-7171). Two modes of demethylation have been documented: site

specific demethylation that coincides in many instances with onset of gene expression of specific genes and a general genome wide demethylation that occurs during early development *in vivo* during cellular differentiation and in cancer cells (Feinberg, A.P. et al. (1983) Nature *301*, 89-92; Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA *83*, 2827-2831). The global demethylation is consistent with the hypothesis that a general demethylase activity which is activated at specific points in development or oncogenesis exists. It has been hypothesized that one mechanism regulating the pattern of methylation is the control of expression of methyltransferase (Szyf, M. (1991) Biochem. Cell Biol. *69*, 764-767) and demethylase activities (Szyf, M.(1994) Trends Pharmacol. Sci. 7, 233-238). Although extensive information has been obtained on the enzymatic activity responsible for methylation and the regulation of its expression in the last two decades (Szyf, M. (1996) Pharmacol. Ther. *70*, 1-37), the identity of the demethylase has remained a mystery. It is clear however that to fully understand how patterns of methylation are formed and maintained and to determine their role in development, physiology and oncogenesis, one has to identify the demethylase enzyme(s). Two main difficulties have inhibited the identification of this enzyme. First, it is believed that demethylation of a methylated cytosine is chemically highly unlikely since it involves breaking a very stable C-C bond. Second, demethylation occurs at very defined stages in development (Brandeis, M. et al. (1993) Bioassays *15*, 709-713) and identifying an adequate tissue source for this enzyme is critical.

Whereas no *bona fide* demethylase has been identified to date, alternative biochemical mechanisms involving exchange of methylated cytosines with non-

methylated cytosines have been described. One previously proposed mechanism is removal of the methylated base by a glycosylase and its replacement with a non-methylated nucleotide utilizing an "excision-repair" mechanism (Razin, A. et al. (1986) Proc. Natl. Acad. Sci. USA *83*, 2827-2831). Glycosylase activities that can remove methylated cytosines from DNA have been demonstrated by Vairapandi and Duker (Vairapandi, M. et al. (1993) *Nucl. Acids Res. 21*, 5323-5327) and more recently by Jost (Jost, J. P. et al. (1995) J. Biol. Chem. *270*, 9734-9739). However it is not clear whether this activity is responsible for the general demethylation observed in cellular differentiation. The fact that the activity identified by Jost acts specifically on hemimethylated sequences (which is not the natural substrate in most cases) and can remove thymidines as well as 5-methylcytosines, supports a repair function for this glycosylase-demethylase (Jost, J. P. et al. (1995) J. Biol. Chem. *270*, 9734-9739). An alternative mechanism involving a RNA dependent activity has been recently described by Weiss et al. (Weiss et al., 1996). This proteinase-insensitive RNA dependent activity has been shown to catalyze the excision and replacement of a methylated CpG dinucleotide with a nonmethylated CpG dinucleotide that is contained in a DNA-RNA hybrid molecule (Weiss, A. et al. (1996) Cell *87*, 709-718). This activity which was identified in differentiating cells in culture was proposed to be involved in demethylation during development. These previous findings demonstrate that the common accepted model in the filed has been that a *bona fide* demethylase does not exist.

It has been previously proposed that the extensive hypomethylation observed in cancer cells might be a consequence of activation of demethylase activity by

oncogenic pathways (Szyf, M.(1994) Trends Pharmacol. Sci. 7, 233-238; Szyf, M. et al. (1995) J. Biol. Chem. *270*, 12690-12696). In accordance with this hypothesis we have shown that ectopic expression of v-Ha-ras had induced demethylation activity in the cells (Szyf, M. et al. (1995) J. Biol. Chem. *270*, 12690-12696). Using an assay that directly measures the conversion of 3'^{32}P labeled methyl dCMP (mdCMP) into dCMP, we have shown that nuclear extracts prepared from P19-Ras transfectants bear high levels of demethylase activity (Szyf, M. et al. (1995) J. Biol. Chem. *270*, 12690-12696). Building on this observation, we hypothesized that cancer cell lines were a good source for demethylase. However, it is not evident that Ras expression in p19 cells does reflect the situation in cancer cells. P19 is an embryonic cell and expression of Ras might be differentiating them.

It would be highly desirable to be provided with a *bona fide* DNA demethylase (DNA dMTase) to alter developmental programs for therapeutic and biological use.

SUMMARY OF THE INVENTION

In accordance with the present invention, we demonstrate the purification of a *bona fide* DNA demethylase (DNA dMTase) from a human lung cancer cell line A549, determine its kinetic parameters and substrate specificity. The DNA dMTase activity identified in this study converts methyl-dCMP (mdCMP) residing in the dinucleotide sequence mdCpG into dCMP whereas the methyl group is released as a volatile residue which was identified to be methanol. The activity is purified away from any trace amounts of dCTP, is insensitive to the DNA polymerase inhibitor ddCTP, is not affected by the presence of methyl dCTP (mdCTP) in the

reaction and does not exhibit exonuclease or glycosylase activities. The identification of this new enzyme points out to new directions in our understanding of how DNA methylation patterns are formed and altered.

One aim of the present invention is to provide a *bona fide* DNA demethylase (DNA dMTase).

In accordance with the present invention there is provided a DNA demethylase enzyme having about 40 KDa, and wherein the DNA demethylase enzyme is over-expressed in cancer cells and not in normal cells.

In accordance with the present invention there is provided a cDNA encoding human demethylase which comprises a sequence set forth in SEQ ID NO:1.

In accordance with the present invention there is provided two mouse cDNAs homologous to the human cDNA, wherein the cDNA encoding mouse demethylase having a sequence set forth in SEQ ID NOS:5-7.

In accordance with the present invention there is provided a different human cDNA which encodes a protein homologous to the human demethylase having a sequence set forth in SEQ ID NO:3.

In accordance with the present invention there is provided the use of the expression of demethylase cDNAs to alter DNA methylation patterns of DNA *in vitro* in cells or *in vivo* in humans, animals and in plants.

The demethylase cDNAs expression may be under the direction of mammalian promoters, such as CMV.

The demethylase cDNAs expression may be under plant specific promoters to alter methylation in plants and to allow for altering states of development of plants and expression of foreign genes in plants.

The demethylase cDNAs expression may be in the antisense orientation to inhibit demethylase in cancer cells for therapeutic processes.

The expression of demethylase cDNA in mammalian cells may be to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

In accordance with the present invention there is provided the use of the expression of demethylase cDNAs in bacterial or insect cells for production of large amounts of demethylase.

In accordance with the present invention there is provided the use of the expression of demethylase cDNAs for the production of protein in vertebrate, insect or bacterial or plant cells, such as antibodies against demethylase.

In accordance with the present invention there is provided the use of the sequence of demethylase cDNAs as a template to design antisense oligonucleotides and ribozymes.

In accordance with the present invention there is provided the use of the predicted peptide sequence of demethylase cDNAs to produce polyclonal or monoclonal antibodies against demethylase.

In accordance with the present invention there is provided the use of expression of cDNAs in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

In accordance with the present invention there is provided the use of expression of cDNAs in bacterial, vertebrate or insect cells to produce large amounts of demethylase for obtaining a x-ray crystal structure and for high throughput screening of demethylase inhibitors for therapeutics and biotechnology.

In accordance with the present invention there is provided a volatile assay for high throughput

screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

a) using transcribed and translated demethylase cDNAs *in vitro* to convert methyl-cytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;

b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.

In accordance with the present invention there is provided a volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

a) determining demethylase activity in patient samples by assaying conversion of methyl-cytosine present in methylated DNA to cytosine present in DNA and its volatilization as methyl groups released as methanol;

b) determining the presence or minute amount of volatilized methyl released as methanol groups as an indication of cancer in the patient sample.

In accordance with the present invention there is provided the use of an antagonist or inhibitor of DNA demethylase for the manufacture of a medicament for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

Such an antagonist is a double stranded oligonucleotide that inhibits demethylase at a Ki of 50nM, such as $\left(C^{m}GC^{m}GC^{m}GC^{m}G\right)_{\left(G^{m}CG^{m}CG^{m}CG^{m}C\right)n}$.

The inhibitors include, without limitation an anti-DNA demethylase antibody, an antisense of DNA demethylase or a small molecule such as any derivative of imidazole.

The change of the methylation pattern may activate a silent gene. Such an activation of a silent gene permits the correction of genetic defect such as found for β-thalassemia or sickle cell anemia.

The DNA demethylase of the present invention may be used to remove methyl groups on DNA *in vitro* such as needed for cloning DNA.

The DNA demethylase of the present invention or its cDNAs may be used, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

The DNA demethylase of the present invention or its cDNAs may be used, for inhibiting methylation in cancer cells using vector mediated gene therapy.

In accordance with the present invention there is provided an assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase by either RT-PCT, ELISA or volatilization assay of the present invention in a sample from the patient, wherein overexpression of the DNA demethylase is indicative of cancer cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A to 1B illustrate the purification of demethylase (DNA dMTase) from human A549 cells;

Figs. 2A and 2C illustrate that DNA dMTase is a protein inhibited by RNA and not by ddCTP, mdCTP;

Figs. 2B and 2D illustrate the kinetics of DNA dMTase activity;

Figs. 3A to 3C illustrate the product of DNA dMTase activity is cytosine and it exhibits no exonuclease or glycosylase activity;

Figs. 4A-4C illustrate the demethylation reaction releases methanol as a volatile residue;

Fig. 4D illustrates the transfer of a proton from water to regenerate cytosine;

Figs. 4E-4F illustrate that the volatile product is methanol;

Fig. 5 illustrates the suggested demethylation reaction;

Figs. 6A-6D illustrate the substrate Specificity of DNA dMTase;

Figs. 7A-7D illustrate chromatographic isolation of dMTase from human A549 cells;

Figs. 8A-8B illustrate the alignment between the MDB domain of MeCP2 and demethylase and the predicted amino acid sequence of human demethylase;

Fig. 8C illustrates the mRNA encoded by demethylase;

Figs. 9A-9F illustrate the cDNA and their predicted amino acid of demethylases and homologues of the present invention (SEQ ID NOS:1-8);

Figs. 10A-B illustrate a mammalian expression vector of dMTase and *in vitro* translated dMTase polypeptide;

Fig. 10C illustrates that *in vitro* translated DNA dMTase releases volatile methyl residues from methylated DNA;

Fig. 10D illustrates that *in vitro* translated DNA dMTase transform methylated cytosines to cytosines;

Fig. 11A illustrates that transiently transfected demethylase releases volatile residues from methylated DNA;

Fig. 11B illustrates the polypeptide expressed from transiently transfected demethylase;

Figs. 11C-11E illustrate that transiently transfected demethylase transforms methylated cytosines to cytosines in a protein dependent manner;

Fig. 11F illustrates that the transformation of methylated cytosine to cytosine by transiently transfected demethylase depends on the concentration of substrate;

Fig. 12A illustrates that transiently transfected demethylase catalyzes the transfer of a proton from tritiated water to regenerate cytosine;

Fig. 12B illustrates that the cloned demethylase releases methanol from methylated DNA;

Figs. 13A-13C illustrate that the cancer cells express demethylase activity whereas normal cells do not;

Fig. 13D illustrates that demethylase mRNA is highly express in cancer cells;

Fig. 14A illustrates demethylase bacterial retroviral and mammalian expression vector;

Fig. 14B illustrates inhibition of demethylase activity by a specific inhibitor;

Fig. 14C illustrates inhibition of tumorigenesis *in vitro* by an inhibition of demethylase;

Fig. 15 illustrates inhibition of tumorigenesis in cell culture by induced expression of demethylase antisense vector;

Fig. 16 illustrates the inhibition of demethylase by a small molecule inhibitor imidazole; and

Fig. 17 illustrates a model for the inhibition of cancer growth by an inhibition of demethylase.

DETAILED DESCRIPTION OF THE INVENTION

The pattern of methylation is fashioned during development by a sequence of methylation and demethylation events. The identity of the demethylase has remained a mystery and alternative biochemical activities have been shown to demethylate DNA but no activity that can truly remove methyl groups from DNA has been

shown to date. Utilizing human lung carcinoma cells as a source for demethylase activity we demonstrate that mammalian cells bear a *bona fide* DNA demethylase (DNA dMTase) activity. DNA dMTase transforms methyl-C to C by catalyzing replacement of the methyl group on the 5 position of C with a hydrogen derived from water. DNA dMTase demethylates both fully methylated and hemimethylated DNA, shows dinucleotide specificity and can demethylate mdCpdG sites in different sequence contexts. This enzyme is different from previously described demethylation activities: it is proteinase sensitive, activated by RNase and releases different products.

DNA dMTase is a novel enzyme showing a new and unexpected activity that has not been previously described in any organism. The finding of a *bona fide* demethylase, points out new directions in our understanding of the biological role of DNA methylation.

In spite of the fact that it was previously shown that Ras expression in p19 cells can induce demethylation activity. It was not clear whether this demethylation activity is indeed a *bona fide* demethylase. One would predict that demethylase is present in embryonal cells. It was surprising to see that demethylation activity is present in cancer cells. The finding of high levels of demethylase in A549 cells is indeed an unexpected discovery.

In accordance with the present invention, it is shown and demonstrated that demethylation occurs by removal of a methyl group from methylated cytosine in DNA, that a hydrogen from water replaces the methyl group at the 5' position, that the resulting methyl group reacts with the remaining hydroxyl from water to generate methanol which volatilizes (Fig. 4E-F). Thus,

bona fide demethylation of DNA involves the following reaction:

$$CH_3\text{-cytosine-(DNA)} + H\text{-}OH \xrightarrow{\text{demethylase}} H\text{-cytosine} + CH_3\text{-}OH$$

The cDNA cloned in accordance with the present invention is the demethylase since it can convert methyl-cytosines in DNA to cytosines and volatilize the methyl groups on DNA when transcribed and translated *in vitro* which are released as methanol. This is a novel cDNA encoding a biochemical activity that has been not described before.

In accordance with the present invention, there is shown a model for the inhibition of cancer growth by an inhibition of demethylase (Fig. 17).

EXPERIMENTAL PROCEDURES

Cell Culture

A549 Lung Carcinoma cells (ATCC: CCL 185) were grown in Dulbecco's modified Eagle's medium (with low glucose) supplemented with 10% fetal calf serum, 2 mM glutamine, 10 U/ml cifrofloxacin. Human Skin Fibroblasts #72-213A MRHF were obtained from BioWhittaker, Bethesda and were grown in Dulbecco's modified Eagle's medium supplement with 2% fetal calf serum, 2 mM glutamine. H446 Lung carcinoma cells (ATCC: HTB 171) was grown in RPMI 1640 medium with 5% fetal calf serum.

Preparation of nuclear extract

Nuclear extracts were prepared from A549 cultures at near confluence as previously described (Szyf et al., 1991; Szyf et al.,1995). The cells were trypsinized, collected and washed with phosphate-buffered saline and suspended in buffer A (10 mM Tris, pH 8.0, 1.5 mM $MgCl_2$, 5mM KCl, 0.5% NP-40) at the concentration of 10^8 cells per ml for 10 min. at 4°C. Nuclei were collected by centrifugation of the suspension at 1000 g

for 10 minutes. The nuclear pellet was resuspended in buffer A (400 µl) and collected as described in the experimental procedures. A nuclear extract was prepared from the pelleted nuclei by suspending them in buffer B (20 mM Tris, pH 8.0, 25% glycerol, 0.2 mM EDTA and 0.4 mM NaCl) at the concentration of $3.3x10^8$ nuclei per ml and incubating the suspension for 15 min. at 4°C. The nuclear extract was separated from the nuclear pellet by centrifugation at 10,000g for 30 minutes. Nuclear extract were stored in -80°C for at least two months without loss of activity.

Chromatography on DEAE-Sephadex

A freshly prepared nuclear extract (1 ml , 1.1 mg) was passed through a Microcon™ 100 spin column, the retainant was diluted to a conductivity equivalent to 0.2 M NaCl in buffer L and applied onto a DEAE-Sephadex column (Pharmacia) (1.0 x 5 cm) that was preequilibrated with buffer L (10 mM Tris-HCl, pH 7.5, 10 mM $MgCl_2$) containing 0.2 M NaCl at a flow rate of 1 ml/min. The column was then washed with 15 ml of the starting buffer (buffer L + 0.2 M NaCl) and proteins were eluted with 5 ml of a linear gradient of NaCl (0.2-5.0 M). 0.8 ml fractions were collected and assayed for demethylase activity after desalting through a Microcon™ 10 spin column (Amicon) and resuspension of the retainant in 0.8 ml buffer L. DNA demethylase eluted between 2-5.0 M NaCl.

Chromatography on S-Sepharose

Active DEAE-Sepharose column fractions were pooled, adjusted to 0.1 M NaCl by dilution and loaded onto an S-sepharose column (Pharmacia) (1.0 x5 cm) which had been preequilibrated with buffer L containing 0.2 M NaCl at a flow rate of 1 ml/min. Following washing of the column as described in experimental procedures, the proteins were eluted with 5 ml of a linear

NaCl gradient (0.2-5.0M). 0.5 ml fractions were collected and assayed for DNA demethylase activity after desalting and concentrating to 0.2 ml using a Microcon™ 10 spin column. DNA demethylase activity eluted around 5.0 M NaCl.

Chromatography on Q-Sepharose

Active fractions from S-sepharose column were pooled, adjusted to 0.2 M NaCl by dilution and applied onto a Q-sepharose (Pharmacia) column (1.0 x5 cm) which had been equilibrated as described in the experimental procedures at a flow rate of 1 ml/min. The column was washed and the proteins were eluted with a linear NaCl gradient (0.2- 5.0 M). Fractions (0.5 ml) were collected, assayed for demethylase activity after desalting and concentrating to a final volume of 0.2 ml as described in the experimental procedures. The demethylase activity eluted around 4.8-5.0 M NaCl.

Gel-Exclusion Chromatography on DEAE-Sephacel

The pooled fractions of Q-sepharose column were adjusted to 0.2 M NaCl, loaded onto a 2.0 x 2.0 cm DEAE-Sephacel column (Pharmacia) and eluted with 10 ml of buffer L containing 0.2 M NaCl. The fractions (0.8 ml) were collected and assayed after concentration to about 180 μl with a Microcon™ 10 spin column for DNA demethylase activity. The activity was detected at fraction 4, which is very near the void volume (~200kDa).

Assay of DNA demethylase activity

To directly assay DNA demethylase activity *in vitro* two independent methods were applied.

(**A**) To assay the conversion of methyl-dCMP (mdCMP) to dCMP we used a previously described method (Szyf et al., 1995). Briefly, α^{32}P labeled, fully methylated poly[mdC^{32}PdG]n substrate was prepared as follows. One hundred ng of a double-stranded fully methylated

(mdCpdG) oligomer (Pharmacia) were denatured by boiling, which was followed by partial annealing at room temperature. The complementary strand was extended with Klenow fragment (Boehringer Mannheim) using methyl-5-dCTP (mdCTP, 0.1 mM) (Boehringer Mannheim) and [α-^{32}P] GTP (100 μCi, 3000 Ci/mmol), and the unincorporated nucleotides were removed by chromatography through a NAP-5 column (Pharmacia). The NAP-5 chromatography was repeated to exclude minor contamination with unincorporated nucleotides. As a control a nonmethylated poly[dC^{32}pdG]n substrate was similarly prepared except that a nonmethylated dCpdG oligomer served as a template and dCTP was used in the extension reaction. The column fractions (30 μl), described in the experimental procedures were incubated with 1 ng of poly[mdC^{32}pdG]n substrate for 1 hour at 37°C in a buffer L containing 25% glycerol (v/v) and 5 mM EDTA. The reacted DNA as well as a nonmethylated poly[dC^{32}pdG]n and methylated [mdC^{32}pdG]n nonreacted controls were purified by phenol/chloroform extraction and subjected to micrococcal nuclease digestion (100 μg at 10 μl) and calf spleen phosphodiesterase (2μg) (Boehringer) (Pharmacia) to 3' mononucleotides for 15 hours at 37°C. The digestion products were loaded onto a thin layer chromatography plate (TLC) (Kodak, 13255 Cellulose), separated in a medium containing, 132 ml Isobutyric acid:40 ml water: 4 ml ammonia solution, autoradiographed and the intensity of the different spots was determined using a phosphorimager (Fuji, BAS 2000). ^{32}P labeled substrates and tritium labeled substrates were phosphoimaged using BAS 2000 plate and BAS-TR2040 phosphorimager plate respectively.

(B) The second method determined removal of methylated residues from methylated DNA by measuring disappearance of ^{3}H-CH$_3$ or ^{14}C-CH$_3$ from the reaction mixture. 100 ng

of poly [dCdG]n double stranded DNA was methylated using SssI methylase (New England Biolabs) and an excess of [^{3}H-methyl AdoMet (80 Ci/mmol; New England Nuclear)]. The tritiated methyl group containing DNA was purified from labeled AdoMet using NAP-5 column chromatography. All column purified fractions of DNA demethylase were assayed using the tritiated substrate. In a typical assay, 1 ng of DNA was incubated (at a specific activity of 4 x10^{6}dpm/mg)with 30 μl of column fraction for one hour at 37°C in buffer L. To determine the number of methyl groups remaining in the DNA following incubation with the different fractions, 250 μl of water were added and the mixture was incubated at 65°C for 5 minutes. One hundred μl of the reaction mixture were withdrawn for liquid scintillation counting. Controls received similar treatment except that in place of a column fraction, an equal volume of buffer L was added. The number of methyl groups that were removed from the DNA by the different fractions was determined by subtracting the remaining counts in each of the fractions from the counts remaining in the control. All tests were carried out in triplicates. The results are presented as picomole methyl group removed. One unit of DNA dMTase activity is defined as: amount of enzyme that releases one picomole of methyl group from methylated dCpdG substrate in one hour at 37°C.

Methyl removal assay using double-labeled substrates

To determine whether the methyl group leaves the DNA and not any non-specific removal of tritium, we prepared SK plasmid DNA containing a tritiated hydrogen at the 6' position of cytosine and thymidine by growing the plasmid harboring bacteria in the presence of deoxy [6-^{3}H] Uridine (22 Ci/mmol; Amersham) (10μCi/ml). The [6-^{3}H]-cytosine containing pBluescript SK(+) was puri-

fied according to standard protocols and was methylated using an excess of [^{14}C-methyl] AdoMet (59 mCi/mmol; Amersham) (10 μCi per 100 μl reaction)and SssI methylase. The double labeled DNA substrate was purified twice on a NAP-5 column. 15 μl of DNA dMTase were incubated with 1 ng of double labeled DNA (specific activity of 2000 dpm/ng) for 1 hour at 37°C. Following incubation, the remaining ^{14}C versus ^{3}H counts were determined as described in the experimental procedures by scintillation counting (Wallac). The ^{14}C counts were normalized against ^{3}H counts. The controls received similar treatment except that instead of DNA dMTase, an equal amount of distilled water was added to them.

To determine the number of ^{3}H-CH_3 in the gaseous phase, 1 ng of ^{3}H-CH_3 poly [dCpdG] DNA were incubated with DNA dMTase overnight in a sealed tube (Pierce, Illinois, USA). 0.8 ml of air were removed from the tube using a gas tight syringe (Hamilton, Reno, Nevada) and injected into a sealed gas tight scintillation vial containing 10 ml OptiPhase scintillation fluid (Wallac, UK) and counted. As a control the DNA was incubated with an equal volume of buffer L and treated similarly.

Synthesis of other methylated dC dinucleotides

Poly [mdC^{32}pdA] and [mdC^{32}pdT] substrates were prepared as follows. About 0.5 μg of 20 mer oligonucleotides 5'(GG)103', 5'(GT)103' and 5'(GA)103' were boiled and annealed at room temperature with oligonucleotide 5'CCCCCC3', 5'CACACA3' and 5'CTCTCT3' respectively. The complementary strand was extended with Klenow fragment using m5dCTP (Boehringer Mannheim) and either [α^{32}P] dATP (100μCi, 3000Ci/mmol) or [α^{32}P] dTTP (100 μCi, 3000 Ci/mmol) respectively. The unincorporated nucleotides were removed by chromatography through a NAP-5 column. Hemimethylated mdCpG substrate was prepared in a similar manner except that a nonmeth-

ylated poly dCpdG substrate (Boehringer) was used as template and m5dCTP and [α^{32}P]dGTP were used for extension as described in the experimental procedures.

Assay for nuclease and glycosylase activity

[^{32}pmdCpdG]n substrate which included a labeled ^{32}P 5′ to mdC was prepared as follows. About 100 ng of poly dCpdG DNA were boiled and partially annealed at room temperature. [α^{32}P]dCTP and cold dGTP were used for complementary strand extension as described in the experimental procedures. The free nucleotides were separated using NAP-5 column chromatography. The purified [^{32}pmdCpdG]n DNA was subjected to methylation by SssI methylase using 320 μM AdoMet. The DNA was repurified twice using a NAP-5 column. The methylated DNA (1 ng) was incubated with either 30 μl DNA dMTase, nuclear extract or buffer L. To determine whether α^{32}P labeled residue is excised from the DNA it was directly applied (3μl) onto a TLC plate. To determine whether the DNA was demethylated it was subjected to digestion with snake venom phosphodiesterase (0.2 mg in a 10μl reaction volume) (Boehringer Mannheim) which attacks the 3′-OH group releasing 5′-mononucleotides. The resulting mononucleotides were separated on TLC plates and autoradiographed.

To test whether dCTP copurifies with DNA dMTase, which may be involved in activities other than *bona fide* demethylation, 20 μM of dCTP with 1 μl of α^{32}P labeled dCTP (3000 Ci/mmole) was loaded onto the column with nuclear extract. The ^{32}P counts were measured in the flow through, washes and in the different fractions. About 1.1 million counts were loaded onto the DEAE-Sepharose column and were all recovered up to fraction 8.

To determine whether DNA dMTase contains a DNA polymerase activity, DNA demethylase reactions were

performed in presence of 500 μM of ddCTP (Pharmacia) or 500 μM of m5dCTP (Boehringer Mannheim) at initial rate conditions.

To determine whether DNA dMTase is sensitive to RNase or Proteinase K treatment, DNA dMTase was pretreated for 1 h at 56°C with 200 μg/ml proteinase K (Sigma). A demethylation reaction was carried out with this pretreated fraction in the usual manner using both demethylation assays described in the experimental procedures. To test the effect of RNA digestion on the demethylation reaction, the fractions from different columns were treated with 100 μg/ml RNase A (Sigma).

Demethylation of pBluescript SK(+) Plasmid

About 4 μg plasmid pBluescript SK (Stratagene) was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated with 30 μl of DNA dMTase Fraction 4 of DEAE-Sephacel column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plasmid were subjected to digestion with 10 units each of either of the restriction endonucleases EcoRII (GIBCO-BRL), DpnI, HhaI or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10 μl for 2 hour at 37°C. Following restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10 μl. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond Nylon membrane and hybridized with pBluescript SK(+) plasmid which was ^{32}P labeled by random-priming (Boehringer Mannheim).

Effect of Redox Reagents (NAD, NADH, NADP, NADPH and $FeCl_3$) on demethylase activity

The reagents were prepared at 100 μM concentration and added at a final concentration of 10 μM to a standard methyl removal assay under initial rate condi-

tions as described in the experimental procedures. The methyl removal activity in presence of each of the cofactors was compared to a control DNA dMTase reaction.

Determination of kinetic parameters

For determination of kinetic parameters, the demethylation reactions were performed using both assays (generation of dCMP and removal of methyl) as described in the experimental procedures except that varying DNA concentrations from 0.1 nM to 2.5 nM were used in a total volume of 50µl including 30 µl of DNA dMTase. Since it has been established by previous experiments that the reaction proceeds for at least 3 hours, the initial velocity of reaction was measured at one hour intervals. The velocity data was collected at each substrate DNA concentration range stated for both assays. The Km and Vmax values for DNA demethylase activity were determined from double reciprocal plots of velocity versus substrate concentration.

Measurements of methanol production catalyzed by demethylase by gas chromatography

Gas chromatography was performed with a Varian™ model 3400 GC equipped with a 30m Stabilwax™ column (0.053 cm i.d.: Restek Corporation). Nitrogen™ was used as carrier gas at a flow rate of 32 ml/min, the injector and detector chambers were at 200 and 300°C respectively. The column was maintained at 40°C for 5 minutes after sample injection.

The demethylase reaction was performed in eppendorf tubes kept within sealed scintillation vials with 300 µl of water as aqueous phase (in radioactive trapping experiments this was replaced by 300 µl of methanol). The demethylase reaction was initiated in buffer L (10 mM $MgCl_2$, 10 mM Tris-HCl pH 8.0) with 500 ng of tritiated SK plasmid (6000 dpm/µl) and 100 µl of demethylase at 37°C. After overnight incubation at 37°C,

the aqueous phase surrounding the eppendorf tube was transferred to a fresh eppendorf tube, 2 µl of this mixture was injected in the gas chromatography using a gas tight syringe (Hamilton, Reno, Nevada).

Coupled *in vitro* transcription translation

The mRNAs encoded by the pcDNA 3.1/His Xpress demethylase constructs described above were transcribed and translated by coupled transcription-translation using Promega™ TNT reticulocyte lysate kit (according to manufacturer's protocol), 2 µg of each construct and 40µCi of [^{35}-S]methionine (1,000Ci/mmol, Amersham) in a 50µl reaction volume. To purify non labeled *in vitro* translated demethylase, coupled *in vitro* transcription and translation was performed as above but in the presence of cold methionine. The translation products were bound to a Probond™ nickel column (Invitrogen) and demethylase was eluted according to the manufacturer's protocol with increasing concentrations of imidazole. Demethylase is eluted at 350-500mM imidazole. The imidazole eluted demethylase was dialyzed and concentrated by lyophilization.

Gas chromatography coupled with Mass spectrometry (GC-MS) Analyses for identification of volatile product of demethylase catalyzed reaction as methanol

The demethylation reactions (volume 50 l) were run in conical vials having a total internal volume of 350 microlitres. The vials were closed with a teflon-lined screw cap and left at room temperature for 18 h. The vials were cooled in an ice bath, opened and 10 mg of NaCl and 50 microlitres of toluene were added. The vials were frequently shaken over a period of 1 h. The toluene phases were pipetted into clean vials in a manner to rigorously exclude water carry over. Anhydrous sodium sulfate (5 mg) was added to the toluene extracts to remove water, and the toluene phases were pipetted

into autoinjector vials for GC/MS analysis. Aliquots of 3 microlitres were analyzed under the following instrumental conditions: Instrument: Hewlett-Packard 5988A; Column: 30 m x 0.25 mm i.d. fused quartz capillary with 0.25 micron DB-1 liquid phase, programmed after an initial hold for 1 min at 70 deg at 5 deg/min to 80 deg, then ramped ballistically to 280 deg for bake-out for 5 min; Injector and interface temperatures: 250 deg; Helium flow rate 1.5 ml/min; Mass spectrometer: ion source 200 deg, 70 eV electron impact ionization, scanning from m/z 10 to 50 in full scan mode was begun 6 s after injection, and ceased at 1.5 min to avoid acquisition of the intense toluene solvent peak.

Human A549 cells bear a demethylase activity that could be purified away from dCTP and DNA MeTase

The use of an appropriate cellular source and a direct assay for demethylase activity are obviously critical. As we have previously shown that demethylase activity was induced in response to ectopic expression of the Ras oncogene (Szyf *et al.*, 1995) we reasoned that cancer cells might bear high levels of demethylase activity. Based on preliminary studies demonstrating the presence of high levels of demethylase activity in the human lung carcinoma cell line A549, we have chosen this cell line for our further studies and purification steps. Previous studies have used indirect measures such as increased sensitivity to methylation-sensitive restriction enzymes as indicators of demethylase activity (Weiss et al., 1996; Jost et al., 1995). To directly measure the conversion of 5-mdCMP in DNA to dCMP, we have utilized a completely methylated ^{32}P labeled [mdC^{32}pdG]n double stranded oligomer which we had previously described (Szyf et al., 1995). Following incubation with the different fractions, the

DNA is purified and subjected to cleavage with micrococal nuclease to 3′ mononucleotides. The 3′ labeled mdCMP and dCMP are separated by thin layer chromatography (TLC) and the conversion of mdCMP to dCMP is directly determined. This assay provides a stringent test for *bona fide* demethylation and discriminates it from previously described 5mCpC replacement activities (Jost *et al.*, 1995; Weiss *et al.*, 1996). The glycosylase-demethylase activity described by Jost et al. (Jost *et al.*, 1995) will require the presence of a ligase activity and an energy source for replacement of mdC with C to be detected by our assay, whereas the demethylase activity described by Weiss et al. will not be detected since it replaces the intact $mdC^{32}pdG$ dinucleotide with a cold dCpdG without altering its state of methylation (Weiss *et al.*, 1996).

Nuclear extracts were prepared from A549 cells, applied onto a DEAE-Sephadex column, eluted with a linear gradient from 0.2-5.0M NaCl and the fractions were assayed for demethylase (dMTase) activity as described in the experimental procedures. As shown in Fig. 1(A) a clear peak of dMTase activity is eluted at the high salt fraction 10.

Conversion of methylated cytosine to cytosine: Nuclear extracts prepared from A549 cells (1.1 mg) were passed through an AMICON™ 100 spin column. The retainant (98.56 mg, 0.2 mg/ml) was loaded onto a DEAE-Sepharose column, the different chromatographic column fractions eluted by a linear NaCl gradient (0.2-5M) were desalted and (30 μl) incubated with 1 ng of $[mdC^{32}pdG]n$ double stranded oligomer for 1 hour at 37°C, digested to 3′ mononucleotides and analyzed on TLC as described in the experimental procedures. Control methylated (ME) and nonmethylated (NM) $[dC^{32}pdG]n$ substrates were digested to 3′ mononucleotides and loaded on the TLC

plate to indicate the expected position of dCMP and mdCMP. The active fraction is indicated by an arrow. This fraction was loaded on S-Sepharose followed by Q-Sepharose and DEAE-Sephacel fractionation.

The first chromatography step purified the dMTase activity from the bulk of nuclear protein (Fig. 1B) and is a very effective purification step.

DNA dMTase activity as measured by the release of volatile methyl residues. The different column fractions were incubated with 1ng (4 x 10^6 dpm/μg) of [^{3}H]-CH_3-[mdCpdG]n oligomer and the release of volatile methyl residues was determined (-) and presented as total dpn). The results are an average of three independent determinations. Protein concentration was determined using the Bio-Rad Bradford kit (-). The elution profile of 20 μM of [^{32}P]-α-dCTP incubated with the protein was determined by scintillation counting of the different DEAE fractions (-) and presented as fraction of dCTP loaded on the column.

To exclude the possibility that the DNA dMTase activity detected in our assay is carried by the DNA MeTase, we assayed the fractions for DNA MeTase activity using a hemimethylated DNA substrate as previously described (Szyf *et al.*, 1991). As observed in Figure 1B DNA MeTase activity is detected in the second and third fractions, thus our fractionation separated DNA dMTase away from the DNA MeTase suggesting that they are independent proteins.

There is a remote possibility that the demethylation observed is not a *bona fide* demethylation but a consequence of a glycosylase removal of mC, followed by removal of the remaining deoxyribose-phosphate by AP (apyrimidine) nuclease, repair of the gap catalyzed by DNA polymerase using trace dCTP contained in the fraction and ligation of the break with ligase in the pres-

ence of residual ATP. For this hypothesis to be consistent with our data, four independent enzymes and two cofactors have to cofractionate with DNA dMTase. To exclude the possibility that a trace amount of dCTP is bound to DNA dMTase active fraction, we have added 20 μM of ^{32}P labeled dCTP ($10x10^6$ cpm) to the nuclear extract and determined its elution profile on the DEAE column. Less than background cpm (10 cpm) were detected in the DNA dMTase active fraction suggesting that our first column purifies dCTP away from the DNA dMTase at least $1x10^6$ fold (Fig. 1B). If any dCTP is present in the nuclear extract, the remaining concentration after fractionation on DEAE is well below the Kms of the known DNA polymerases. The possibility that dCTP is so tightly bound to the enzyme that it could not be replaced by the exogenous ^{32}P labeled dCTP is very remote since an enzyme using dCTP as substrate must readily exchange dCTP.

The active fraction 10 was further fractionated sequentially on the following columns: S-Sepharose and Q-Sepharose. The DNA dMTase eluted at the high salt fraction from both columns as determined by the [mdC^{32}pdG]n demethylation assay (Fig. 1A). The ion exchange chromatography was followed by chromatography on DEAE-Sephacel.

The fact that we have maintained our activity even after 4 fractionation steps (Table 1) and that only a single polypeptide is apparent after the last purification step argues strongly against the possibility that the activity detected in our study is a repair or replacement activity. Any replacement mechanism must involve a number of proteins and additional cofactors and substrates. In summary, the chromatography of the demethylase activity in A459 cells provides strong

support to the hypothesis that mammalian cells bear a *bona fide* demethylase activity.

DNA dMTase releases a volatile derivative

A *bona fide* demethylation has to result in release of the methyl group as a volatile derivative such as CO_2, methanol, methane or formaldehyde. We have therefore incubated a {[^{3}H] -CH_3-dCpdG}n double stranded oligonucleotide with the different column fractions and the rate of release of the tritiated methyl from the aqueous phase was determined by scintillation counting of the remaining radioactivity in the reaction mix. As demonstrated in Fig. 1b (diamond), the dMTase active fractions release labeled methyl groups from the methylated substrate.

DNA dMTase is a protein which is inhibited by RNA, does not involve an exchange activity and does not require additional cofactors

DNA dMTase activity measured either as transformation of mdC to C (Fig. 2a) or as release of volatile methyl residues (Fig. 2c) is abolished after proteinase K treatment and is not inhibited but rather enhanced following RNase treatment. 500 μM of ddCTP which inhibits DNA polymerase does not inhibit demethylation of the [mdC32pdG]n substrate, nor is it inhibited by high concentrations of methyl-dCTP (500 μM) (Fig. 2a), which is consistent with the hypothesis that demethylation does not involve an excision and replacement mechanism. If a replacement mechanism is involved in demethylation, the presence of mdCTP should result in incorporation of methylated cytosines and essential inhibition of demethylation. Thus, the DNA dMTase identified here is a protein and not an RNA and is unequivocally different from the previously published RNA based or glycosylase based demethylase activities.

The DNA dMTase reaction proceeds without any requirement for additional substrates such as dCTP, redox factors such as NADH and NADPH or energy sources such as ATP (data not shown). As observed in Fig. 2b and 2d, the DNA dMTase reaction maintains its initial velocity up to 90 minutes and continues up to 120 minutes. This time course is inconsistent with dependence on enzyme-bound additional nonreplenishable substrates such as dCTP or ATP or a nonreplenishable redox factor such as NADH or NADPH. Exhausting the nonreplenishable substrate or redox factor would have resulted in rapid deceleration of the initial velocity.

A product of the demethylation reaction is deoxyCytosine in DNA

What is the product of the demethylation reaction? The results presented above (Fig.1a, 2a and b) based on a one dimension TLC separation show that DNA dMTase generates dC from mdC in DNA. To further substantiate this conclusion, we subjected DNA dMTase treated DNA to remethylation with the CpG MeTase M.*Sss* I which can transfer a methyl group exclusively to dC. The results presented in Fig. 3a show that the demethylated product of DNA dMTase is dC since it is completely remethylated with M.*Sss* I. The identity of the demethylated product as dC was further established by a two-dimension TLC analysis demonstrating that the product of dMTase comigrates with a cold dCMP standard in both dimensions (Fig. 3b).

DNA dMTase does not release a nucleotide, a phosphorylated base or phosphate from methylated DNA when incubated with a [32pmdCpdG]n substrate which included a labeled 32P 5′ to mdC or our standard methylated substrate (Fig.1) where 32P is 3′ to the m5dC (Fig. 3c). Nuclear extracts which obviously contain a number of glycosylases and nucleases release phospho-

rylated derivatives in the same assay (Fig. 3c). dMTase transforms the methyl cytosine in the [32pmdCpdG]n substrate to cytosine as demonstrated when the reacted DNA is digested to 5' mononucleotides (Fig. 3c +V PDS) and analyzed by TLC. Since this reaction does not involve release of a 32P derivative (Fig. 3c -V PDS), it demonstrates that dMTase transforms methylated cytosines to cytosines on DNA without disrupting the integrity of the DNA substrate by glycosylase or nuclease activity .

The second product of the dMTase reaction is methanol

What is the identity of the leaving group? The results presented in Fig1b suggest that the labeled methyl leaves the DNA as a volatile compound. The demethylase reaction involves release of the methyl group *per se* whereas the cytosine base ring remains in the aqueous phase. Fig. 4a demonstrates this point by using a methylated plasmid labeled with a ^{3}H-hydrogen at the sixth position of cytosine and [14C]-methyl at the fifth position of cytosine as a substrate.

The three most obvious candidates the methyl group is leaving as are formaldehyde, carbon dioxide, and methanol. Methadone trapping for labeled formaldehyde detection and sodium hydroxide trapping for labeled carbon dioxide detection were both negative in identifying the form in which the methyl group is leaving in the dMTase reaction (data not shown). The other possible chemical form that the methyl group may leave the DNA as, is methanol. Since methanol is a volatile compound, a simple method to measure generation of methanol is a scintillation-volatilization assay (see Fig. 4b for description). Volatilization assays have been previously used to measure release of methanol in demethylation reactions. The demethylation reaction mix containing the labeled {[^{3}H] -CH_3-dCpdG}n substrate

with either dMTase or no enzyme, as a control, is added to an uncapped 0.5 ml tube which is placed in a sealed scintillation vial containing scintillation fluid. Released methanol is volatile, diffuses out of the open reaction tube and is mixed with the excess of the scintillation fluid in the vial registering as counts in the scintillation counter. As a control indicating that methanol is volatilized under the conditions of our assay, we incubated approximately equal counts of radioactively labeled methanol under the same conditions and measured the counts in a scintillation counter at different time points. As observed in Fig. 4c the majority of methanol in the reaction tube volatilizes from the reaction tube into the scintillation fluid following an overnight incubation at 37°C. The experiment shown in Fig. 4b demonstrates that volatilized label is released from methylated DNA only in the presence of dMTase.

The identity of the volatile group has been determined to be methanol by a gas chromatography (GC) analysis. The demethylation and control reactions (indicated in Fig. 4e) were performed in an uncapped tube placed in a sealed scintillation vial containing a larger volume (300μl) of water. The volatile residue diffuses into the surrounding water and mixes with it. A 2 μl sample of the surrounding water was injected into a GC column as described in the methods. As shown in Fig. 4e, the volatile compound released by dMTase in a dose response manner coelutes with methanol. Release of methanol is observed only in the presence of both dMTase and methylated DNA. No methanol is released when dMTase is reacted with nonmethylated DNA, demonstrating that methanol is a product of demethylation of DNA.

The leaving group was also identified as methanol using gas chromatography coupled with Mass spectrometry (GC-MS). As illustrated in Fig. 4f., incubation of methylated DNA with dMTase (dMTase+ME-DNA) results in release of a peak with the retention time and mass spectrum (peaks are identified at 32 and 29 atomic mass which are the atomic masses of methanol and ionized methanol respectively) which is consistent with its identification as methanol. Incubation of dMTase with nonmethylated DNA does not release methanol indicating that methanol is a product of the demethylation reaction. No methanol is released when the samples are incubated with dMTase treated with protease K indicating that the release of methanol from methylated DNA is catalyzed by an enzymatic activity.

Demethylation involves transfer of a hydrogen from water to regenerate cytosine

If demethylation involves removal of the methyl moiety from mdC, a hydrogen has to be transferred to the carbon at the 5' position to regenerate cytosine. Since no redox factors are involved, what is the source of the hydrogen? To test the hypothesis that the source of the hydrogen is water, we incubated either non labeled [mdCpdG]n or [dCpdG]n double stranded DNA with DNA dMTase for different time periods in the presence of tritiated water, following which the DNAs were digested to 3' dNMPs, separated on TLC with non-radioactive standards for each of the 5 possible dNMPs and exposed to a tritium sensitive phosphorimaging plate. As seen in Fig.4d, dMTase catalyzes the transfer of a tritiated hydrogen from water to dCMP in methylated DNA in a time dependent manner only when methylated DNA is used as a substrate. Based on the experiments described in Fig.3 and 4 we propose that dMTase catalyzes the exchange of the methyl group at

the 5′ position of cytosine in DNA with hydrogen from water and the methyl group reacts with the remaining hydroxyl group to form methanol (Fig. 5).

Substrate and sequence specificity of DNA dMTase

Methylation of CpG dinucleotides is the most characterized modification occurring in genomic DNA8,48. The results presented in Fig.6 demonstrate that DNA dMTase is a general DNA dMTase activity that demethylates fully or hemimethylated dCpdG in DNA flanked by a variety of sequences which are distributed at different frequencies, but does not demethylate methylated adenines or methylated cytosines that do not reside in the dinucleotide CG. First, as shown in Fig.6a, a plasmid DNA methylated *in vitro* at all dCpdG sites with M.*Sss* I and all d*CdCdGdG sites with M. *Msp* I (which methylates the external C in the sequence *CCGG, thus enabling the determination of demethylation at the CC dinucleotide) and in *vivo* with the *E. coli* DCM MeTase at dCmdCdA/dTdGdG sites and with the DAM MeTase at dGmdAdTdC sites (adenine methylated) was treated with dMTase and the state of methylation of the plasmid was determined using the indicated methylation sensitive restriction enzymes. dMTase demethylates C*G methylated sites as indicated by the sensitivity of the dMTase treated plasmid to *Hpa* II and *Hha* I but does not demethylate C*C,C*A or C*T methylated sites as indicated by the resistance to *Msp* I and *Eco* RII restriction enzymes, or adenine methylation as indicated by its sensitivity to *Dpn* I. Second, bisulfite mapping analysis of methylation of 5 methylated C*G sites residing in a M.*Sss* I *in vitro* methylated pMetCAT plasmid following dMTase treatment shows that all C*G sites are demethylated irrespective of their flanking sequences thus excluding the possibility that demethylation is limited to CCGG or CGCG sequences (Fig. 6b).

Third, dMTase does not demethylate two fully methylated cytosine bearing oligomers [dmC32pdA]n, [mdC32pdT]n demonstrating that mdCpdA and mdCpdT are not demethylated by DNA dMTase (Fig. 6d). Fourth, dMTase demethylates a hemimethylated synthetic substrate [dCpdG]n*[mdC32pdG]n (Fig. 6d). Demethylation of SK is complete under these conditions (Fig. 6a) whereas demethylation of a methylated [mdCpdG]n substrate is not complete under the same conditions (Fig. 6d). This can reflect differences in the sequence composition of the substrate and the frequency of methylated cytosines. The [mdCpdG]n contains on average 16 fold more methylated cytosines per molecule than plasmid DNA. Alternatively, these differences might reflect discrepancies in the assays used, restriction enzyme digestion versus a nearest neighbor analysis. To address this discrepancy we have labeled a fully methylated SK plasmid with [α^{32}P]dCTP, 5-methyl-dCTP and the other dNTPs, subjected it to dMTase treatment and digested it to mononucleotides at different time points following the initiation of the reaction and subjected the samples to a TLC analysis. As shown in Fig. 6c, the SK plasmid is fully demethylated at 3 hours which is consistent with the results obtained with methylation sensitive restriction enzymes (Fig. 6a).

The Km of DNA dMTase for hemimethylated and fully methylated DNA was determined by measuring the initial velocity of the reaction at different concentrations of substrate (Table 2). The calculated Km for hemimethylated DNA is 6 nM which is two fold higher than the Km for DNA methylated on both strands, 2.5-3 nM (Table 2). It is unclear yet whether this small difference in affinity to the substrate has any significance in a cellular context. Thus similar to the DNA MeTase DNA dMTase shows dinucleotide sequence

selectivity but in difference from DNA MeTase which shows preference to hemimethylated substrates dMTase prefers fully methylated DNA which is consistent with a role for DNA dMTase in altering established methylation patterns.

Table 1

Purification of DNA dMTase

Purification step	Total protein (µg)	Total dpm	pMole/µg	pMole/µg/h	Fold Purification
Nuclear extract	6000	1107.2	5.5×10^{-5}	1.833×10^{-5}	-
DEAE-Sephadex	3.75	5844	0.4674	0.156	8445.5
SP-Sepharose	0.77	5106	1.989	0.663	35939.84
Q-Sepharose	0.46	5335	3.4	1.13	62860.65
DEAE-Sephacel	0.018	1834	30.57	10.19	552243.2

Table 2

Kinetic parameters for DNA dMTase

Method	K_m (DNA)	V_{max} (pMole/h)
Methylated oligo CpG	2.5 nM	340
Hemi-methylated CpG	6.0 nM	402
Methylated SK-DNA	3.3 nM	40.42

Cloning and construction of demethylase expression vectors

PCR amplification of the MBD domain of the putative demethylase candidate cDNA

One µg of total RNA prepared from the human small lung carcinoma cell line A549 was reverse transcribed using Superscript reverse transcriptase and random primers (Boehringer) in a 25 µl reaction volume according to conditions recommended by the manufacturer (GIBCO-BRL). Five µl of reverse transcribed cDNA were subjected to an amplification reaction with Taq polymerase (Promega, 1 unit) using the following set of

primers: sense 5'CTGGCAAGAGCGATGTC 3' SEQ ID NO:9, antisense 5'AGTCTGGTTTACCCTTATTTTG 3' SEQ ID NO:10.

Amplification conditions were: step 1. 95°C 1 min.; step 2: 94°C 0.5 min; step 3: 45°C 0.5 min.; step 4: 72°C 1.5 min; steps 2-4 were repeated 30 times. $MgCl_2$ was adjusted to 1 mM according to conditions recommended by the manufacturer. The PCR products were cloned in pCR2.1 vector (InVitrogen) and the sequence of the cDNAs was verified by dideoxy-chain termination method using a T7 DNA sequencing kit (Pharmacia). The amplified fragment was excised from the plasmid with EcoRI, labeled with a Boehringer random prime labeling kit according to manufacturer's protocol and alpha ^{32}P-dCTP. The labeled probe was used to screen a HeLa cell cDNA library in λTriplEx phage (Clontech) according to standard procedures. Positive clones were identified and further purified by serial dilutions for 4 rounds. The insert in the pTriplEx plasmid was excised from the phage according to manufacturer's protocols and the identity of the insert was verified by sequencing. The insert was excised by NotI restriction and subcloned into either the inducible expression vector: Retro tet on (Clontech) in the sense and antisense orientation or the pcDNA3.1/His Xpress vector in all three frames and in the antisense orientation.

Transfection and expression of demethylase in vertebrate cells

Ten μg of either Retro tet on demethylase or pcDNA 3.1/His Xpress demethylase are mixed with 8 μl of transfection lypophilic reagent Pfx-2 (Invitrogen) and placed upon 100,000 mouse (3T3 Balb/c, human (A549) or monkey cells (CV-1) according to manufacturer's protocol in OPTIMEM medium for 4 hours. Cells are harvested after 48 hours and demethylation and demethylase activity is determined by measuring total genomic DNA meth-

ylation using standard techniques or a cotransfected *in vitro* methylated plasmid using a HpaII /MspI restriction enzyme analysis. Cellular transformation is measured by a soft agar assay.

Demethylation of pBluescript SK(+) Plasmid

About 4 μg plasmid pBluescript SK (Stratagene) was subjected to methylation using SssI methylase. The methylated plasmid (4 ng) was incubated for different time points as indicated with 30 μl of DNA dMTase Fraction 4 of DEAE-Sephacel™ column under standard conditions, extracted with phenol: chloroform and precipitated with ethanol. About 1 ng of the plasmid were subjected to digestion with 10 units each of either of the restriction endonuclease EcoRII (GIBCO-BRL), DpnI, or HpaII (New England Biolabs) before and after methylation as well as after DNA dMTase treatment in a reaction volume of 10 μl for 2 hour at 37°C. Following restriction digestion the plasmids were extracted with phenol:chloroform, ethanol precipitated and resuspended in 10 μl. The plasmids were electrophoresed on a 0.8% (w/w) Agarose gel, transferred onto a Hybond™ Nylon membrane and hybridized with pBluescript SK(+) plasmid which was ^{32}P labeled by random-priming (Boehringer Mannheim).

dMTase activity coelutes with a ~45 KDa polypeptide when sized under denaturing conditions but migrates as a higher molecular weight complex under non denaturing conditions. dMTase was purified up to 500,000 fold by four chromatographic steps (Table 1). We first determined the identity of the polypeptide associated with dMTase activity by SDS-PAGE analysis of the active fractions. As observed in Fig. 7a, a cluster of 4 polypeptide bands from ~44 KDa to 35 KDa coelute with dMTase activity in the last two chromatographic steps

(the lower fragment might be a degradation product as evidenced by its abundance in the later chromatographic steps). However when the active DEAE-Sephacel fraction is size fractionated on a 4% non denaturing acrylamide column, the dMTase activity elutes at the high molecular weight of ~170 KDa (Fig. 7c, fraction 63). SDS-PAGE analysis of this fraction (63) reveals only two bands (Fig. 7b) observed in the active chromatographic fractions (Fig. 7a) To further determine whether dMTase is found in a multimeric complex, fraction 63 was size fractionated on a glycerol gradient (Fig. 7d) and DNA dMTase activity eluted at the ~170 kDa range. As only two main small polypeptides were identified in fraction 63 (approximately 35-43 KDa), dMTase is probably found in either a homomeric complex if only one of the two peptides is dMTase or a heteromeric complex if both polypeptides are associated with dMTase activity.

a. Identification of a lead DNA dMTase candidate by homology search of dbEST

As the purification of dMTase suggests that the dMTase is of very low abundance, only ~19 ng of dMTase could be isolated from 6 mg of nuclear extract (Table 1), we opted for cloning the dMTase based on its following functional properties. First, since dMTase specifically demethylates methylated CG dinucleotides, we assumed that it should bear the ability to recognize methylated CG dinucleotides. Second, the demethylase transforms methylated cytosine in DNA to cytosine. Third, the demethylase releases the methyl group as a volatile compound.

Previous reports have shown that proteins interacting with methylated DNA share a common domain (MDBD). A TBLASTN search of the dbEST database identified a novel expression tag cDNA (from a T-cell lymphoma Homo sapiens cDNA 5' end) (gb/AA361957/AA361957

EST71295) and the mouse homologue ((gb/W97165/W97165 mf90g05.r1) from Soares mouse embryo NbME13.5) with unknown function that bears homology to the MDBD (Fig. 8a). A search of the GenBank database verified that it is a novel cDNA that has not been included in GenBank. Alignment of the novel EST and MeCP2 and MeCP1 associated protein has revealed no homology beyond the previously characterized MDBD which is consistent with a different function for this methylated DNA binding protein. A 201bp fragment bearing the sequence identified in the search was reverse transcribed and amplified from human lung cancer cell line A549 RNA and was used to screen a cDNA library from Hela cells. The largest insert cloned was of 1.36 kb size and its sequence identity with the EST sequence was determined. The cDNA is novel and has no homologue in GenBank and no function has ever been assigned to it. A virtual translation of the protein identified an open reading frame (ORF) of 262 amino acids (Fig. 8b). The ORF may extend further 5' as no in frame stop codon was found upstream of this ATG. However, RACE analyses and further searches of the dbEST have failed to identify 5' sequences upstream to the one identified in our screening.

A BLAST search of the candidate protein using the Predict protein server against a database of protein domain families has identified only the MDBD domain and found no homologue to the sequence in the data base search. No other functional motifs were identified by the Prosite analysis. This is consistent with a novel biochemical function for this protein. A coiled coil prediction of the sequence identified a coiled coil domain which is known to play a role in protein protein interactions.

The identified cDNA encodes an mRNA that is widely expressed in human cells as revealed by a Northern blot analysis of human poly A+ mRNA (Fig. 8c) as one major transcript of ~ 1.6 kb which is close to the size of the cloned cDNA, verifying that the cloned cDNA does not represent a highly repetitive RNA but rather a mRNA encoded by a single or low copy number gene.

In vitro translated candidate cDNA bears dMTase activity

A conclusive proof for the existence of a single protein that *bona fide* demethylates DNA is to demonstrate that an *in vitro* translated candidate cDNA can volatilize methyl groups from methylated DNA and transform a methyl cytosine to cytosine in an isolated system. The candidate dMTase cDNA was subcloned it into a pcDNA3.1/His Xpress (INVITROGEN) expression vector in the putative translation frame (pcDNA3.1His A) and in a single base frame shift (pcDNA3.1His B), and was *in vitro* transcribed and translated in the presence of ^{35}S-methionine and the resulting translation products were resolved by SDS-PAGE. Autoradiography revealed a ~40KDa protein (Fig. 10a). The apparent size of the *in vitro* translated protein is shorter by ~3-5 KDa from the apparent size of the purified protein. The cloned cDNA might be missing some upstream amino acids as discussed above or might be differently modified in human cells.

Two tests established whether the *in vitro* translated candidate cDNA is a *bona fide* dMTase. We first tested whether *in vitro* translated protein (purified on a Ni2+ charged agarose resin) can volatilize and release methyl residues in [^{3}H]-CH_3-DNA using a radioactive trapping volatilization assay. To verify that the volatilized counts are true ^{3}H counts, a spectrum analysis was performed. As demonstrated in Fig.

10b no volatilization of tritiated methyl residues is observed in the misframe dMTase (misframe) whereas *in vitro* translated putative dMTase cDNA catalyzes the volatilization of ^{3}H-CH_3 residues which are trapped in the scintillation cocktail.

Second, *in vitro* translated dMTase cDNA transforms CH_3-cytosine residing in [^{32}P]-α-dGTP labeled plasmid DNA or in [methyl-dC32pdG]n double stranded oligomer DNA to cytosine, whereas a frame shift *in vitro* translated dMTase does not demethylate DNA (Fig. 10d). This demonstrates that the dMTase activity is dependent on the dMTase translation product and not a contaminating activity found in the *in vitro* translation kit that copurifies with the putative dMTase. The reaction carried out by the *in vitro* translated dMTase displays: dependence on the dose of *in vitro* translated product (Fig. 10c), time dependence (Fig. 10d) and dependence on translated protein (Fig. 10b & d misframe, Fig. 10c protease K treatment). Taken together, these results strongly suggest that the cDNA cloned here codes for a *bona fide* enzymatic DNA demethylase activity.

Transiently transfected dMTase cDNA demethylates DNA

dMTase cDNA and the pcDNA3.1HisC vector control were transiently transfected into human embryonal kidney cells to test whether the cDNA can direct expression of dMTase activity in human cells. The His-tagged proteins were bound to Ni2+ agarose resin and eluted from the resin with increasing concentrations of imidazole. The expression of the transfected dMTase was verified by a Western blot analysis (Fig. 11b). The imidazole fractions were assayed for their ability to volatilize and release methyl residues in [^{3}H]-CH_3-DNA using a radioactive trapping volatilization assay 1. As observed in Fig. 11a, imidazole fractions from

dMTase transfected cells volatilize [^{3}H]-CH_3 whereas no tritiated counts are detected in DNA treated with imidazole fractions from cells transfected with a misframe mutation of dMTase or non transfected cells. The transiently expressed dMTase transforms methylated cytosine in DNA to cytosine residing in two different substrates (Figs. 11c & 11d), in a protein dependent manner (Figs. 11c & 11e), and the reaction displays substrate dependence and saturability (Fig. 11f). Transiently expressed dMTase was loaded on a non denaturing glycerol gradient to determine its native MW. Similar to dMTase purified from human cells, cloned and purified dMTase activity fractionated at the 160-190 KDa range (data not shown). This is consistent with self association of cloned dMTase possibly mediated by the coiled-coil domain.

Cloned DNA dMTase catalyzes a hydrolysis of 5-methylcytosine to release methanol

We determined the mechanism by which methyl residues are released by the cloned dMTase (from Fig. 11) and compared it to the purified *bona fide* dMTase activity. Increasing amounts of non labeled [methyl-dCpdG] DNA were incubated with either the *bona fide* dMTase activity purified from A549 cells or the cloned dMTase in the presence of [^{3}H] water for 3 hours followed by digestion to mononucleotides, a thin layer chromatography and autoradiography. As Fig. 12a shows, both reactions replace the methyl group in 5-methylcytosine with a proton donated from water as indicated by the presence of [^{3}H] label in cytosine.

The identity of the leaving methyl group in the demethylation reaction catalyzed by the purified bona fide dMTase activity was shown to be methanol. In order to identify the form that the methyl residue leaves as in the demethylation reaction catalyzed by

the cloned dMTase an identical gas chromatography/mass spectrometry analysis of the reaction products was performed as in1. Only the properly translated form of dMTase (both *in vitro* translated and transiently transfected and purified) is able to produce ions characteristic of methanol in a mass spectrometric analysis (mass of 32 and 29, Fig. 12b). These results suggest that the demethylation reaction catalyzed by the cloned dMTase is hydrolysis of the 5-methyl-cytosine to cytosine and methanol as described for the purified dMTase1.

DNA dMTase activity is undetectable in nontransformed cells

The assays for dMTase activity described here and the cloning of DNA dMTase cDNA enables a study of its expression at different cellular states. Global hypomethylation of DNA is a common observation in cancer cells. This has been a perplexing observation, since DNA MeTase activity is elevated in cancer cells. Hyperactivation of DNA MeTase has been proposed to play a role in cancer development. This paradox raises questions on the proposed role of the elevated levels of DNA MeTase in cancer cells. One simple explanation that has been previously suggested to resolve this paradox is that cancer cells express induced levels of DNA dMTase. We compared the DNA dMTase activity in equal concentrations of DEAE-Sephadex fractionated nuclear extracts (fractions 9-10) prepared from a number of carcinoma cell lines H446, Colo 205, Hela, and A549 with a similar preparation from human skin fibroblast cells at initial rate conditions using [mdC32pdG]n double stranded oligomer as a substrate. As observed in Fig. 13a, whereas DNA dMTase activity is readily observed in all carcinoma cell lines, it is undetectable in nontransformed human cells. The absence of dMTase activity in human primary cells

reflects the situation *in vivo* since dMTase activity is undetectable in preparations from different murine tissues whereas dMTase activity is present in a murine carcinoma cell line P19 that was transfected with the H-Ras protooncogene, or human tumors carried as xenografts in the same strain of mouse (Fig. 1a: COLO 205, A549. Hela). These conclusions were verified using the radioactive-trapping volatilization assay shown in Fig. 13c.

Since dMTase mRNA has been detected using a sensitive poly A+ Northern blot in all normal human tissues, we tested the hypothesis that the absence of detected dMTase activity in normal tissues reflects a quantitative difference in DNA dMTase mRNA between normal tissues and cancer lines. A Northern blot analysis and quantification of dMTase mRNA by a slot blot analysis shown in Fig. 13d using total RNA supports this hypothesis. Whereas minute levels of dMTase mRNA are detected in normal tissues, high levels of dMTase are expressed in a murine carcinoma cell line Y1 that bears a 30 fold amplification of *Ha-ras*.

A second DNA demethylase dMTase2 identified in human and mouse

cDNA sequences, predicted amino acid sequences, and GenBank accession numbers of both dMTase1 and dMTase2 from human and mouse are shown. We claim that the high level of identity of the two proteins (Figs 9c and e) suggests that the two proteins can perform the same function, DNA demethylation. The N-terminals of dMTase1 and dMTase2 contain a Methylated DNA Binding Domain (MBD) and near their C-terminals is a coiled-coil domain, however the middle portions of the protein sequences have no homology to any know structural or catalytic motif. Importantly, their middle regions are still extensively homologous suggesting that the cata-

lytic site of the demethylase activity lies in this area on both proteins.

Induced expression of DNA demethylase in the Antisense orientation inhibits tumorigenesis *ex vivo*

To test the hypothesis that inhibition of DNA dMTase can inhibit tumorigenesis tetracycline inducible vectors carrying the human dMTase1 cDNA in either the sense or antisense orientation were constructed and transiently transfected into HEK 293 cells, treated for 48 hours either in the presence or absence of doxycycline (a tetracycline analogue), selected for the last 24 hours with puromycin, and then plated on soft agar and allowed to grow for seven days. After seven days colonies were scored and the data presented clearly show that doxycycline induced expression of the dMTase1 cDNA in the antisense orientation reduced colony formation (Fig. 15).

Imidazole is a small molecule inhibitor of DNA demethylase activity

A template small molecule, imidazole, was tested for the ability to inhibit DNA dMTase activity. In a volatilization of radioactive methyl residues assay, concentrations from 1μM to 10mM of imidazole were incubated in a typical volatilization of radioactive methyl residues as described above. The graph clearly demonstrates a dose dependent inhibition of DNA dMTase activity by imidazole, and validates a rationale for testing imidazole based molecules as inhibitors of DNA dMTase activity (Fig. 16).

Identification of DNA demethylase cDNAs and protein sequences

Fig. 9a illustrates cDNA sequence of human dMTase1 (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2), including its Genbank location. **Fig. 9b** illustrates cDNA sequence of human dMTase2 (SEQ ID NO:3) and its predicted amino acid sequence(SEQ ID NO:4), includ-

ing its GenBank location. **Fig. 9c** illustrates protein sequence alignment of human dMTase1 and human dMTase2. **Fig. 9d** illustrates cDNA sequence of mouse dMTase1 (SEQ ID NO:5) and its predicted amino acid sequence (SEQ ID NO:6), including its GenBank location. **Fig. 9e** illustrates cDNA sequence of mouse dMTase2 (SEQ ID NO:7) and its predicted amino acid sequence (SEQ ID NO:8), including its GenBank location. **Fig. 9f** illustrates protein sequence alignment of mouse dMTase1 and mouse dMTase2.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A DNA demethylase enzyme and/or homologue thereof having about 40 KDa, and wherein said DNA demethylase enzyme is overexpressed in cancer cells.

2. A cDNA encoding a human demethylase which comprises a sequence set forth in SEQ ID NOS:1 and 3.

3. A cDNA homologous to the cDNA of claim 2, wherein said cDNA encoding mouse demethylase set forth in SEQ ID NOS:5 and 7.

4. The use of the expression of demethylase cDNA of claims 2 or 3 to alter DNA methylation patterns of DNA *in vitro* in cells or *in vivo* in humans, animals and in plants.

5. The use of claim 4, wherein said demethylase cDNA expression is under the direction of mammalian promoters.

6. The use of claim 5, wherein said promoter is CMV.

7. The use of claim 4, wherein said demethylase cDNA expression is under plant specific promoters to alter methylation in plants and to allow for altering states of development of plants and expression of foreign genes in plants.

8. The use of claim 4, wherein said demethylase cDNA expression is in the antisense orientation to inhibit demethylase in cancer cells for therapeutic processes.

9. The use of claim 9, wherein expression of demethylase cDNA in mammalian cells is to alter their differentiation state and to generate stem cells for therapeutics, cells for animal cloning and to improve expression of foreign genes.

10. The use of the expression of demethylase cDNA of claims 2 or 3 in bacterial or insect cells for production of large amounts of demethylase.

11. The use of the expression of demethylase cDNA of claims 2 or 3 for the production of protein in vertebrate, insect or bacterial cells.

12. The use of claim 11 for producing antibodies against demethylase.

13. The use of the sequence of demethylase cDNA of claim 2 as a template to design antisense oligonucleotides and ribozymes.

14. The use of the predicted peptide sequence of demethylase cDNA of claim 2 to produce polyclonal or monoclonal antibodies against demethylase.

15. The use of expression of cDNA of claim 2 or 3 in two hybrid systems in yeast to identify proteins interacting with demethylase for diagnostic and therapeutic purposes.

16. The use of expression of cDNA of claim 2 or 3 in bacterial, vertebrate or insect cells to produce large amounts of demethylase for high throughput screening of

demethylase inhibitors for therapeutics and biotechnology and for obtaining the x-ray crystal structure.

17. A volatile assay for high throughput screening of demethylase inhibitors as therapeutics and anticancer agents which comprises the steps of:

a) using transcribed and translated demethylase cDNA of claim 2 or 3 *in vitro* to convert methyl-cytosine present in methylated DNA samples to cytosine present in DNA and volatilize methyl group;

b) determining the absence or minute amount of volatilize methyl group as an indication of an active demethylase inhibitor.

18. A volatile assay for the diagnostics of cancer in a patient sample which comprises the steps of:

a) determining demethylase activity in patient samples by determining conversion of methyl-cytosine present in methylated DNA to cytosine present in DNA and volatilization of the methyl group released as methanol;

b) determining the presence or minute amount of volatilized methyl group as an indication of cancer in said patient sample.

19. Use of an antagonist or inhibitor of DNA demethylase of claim 1 or 2 for the manufacture of a medicament for cancer treatment, for restoring an aberrant methylation pattern in a patient DNA, or for changing a methylation pattern in a patient DNA.

20. Use according to claim 19, wherein said antagonist is a double stranded oligonucleotide that inhibits demethylase at a Ki of 50nM.

21. Use according to claim 20, wherein said oligonucleotide is $\begin{matrix}(C^mGC^mGC^mGC^mG)\\(G^mCG^mCG^mCG^mC)_n\end{matrix}$.

22. Use according to claim 19, wherein the inhibitor comprises an anti-DNA demethylase antibody or an antisense oligonucleotide of DNA demethylase or a small molecule.

23. Use according to one of claims 19 or 22, wherein the change of the methylation pattern activates a silent gene.

24. Use according to claim 23, wherein the activation of a silent gene permits the correction of genetic defect.

25. Use according to claim 24, wherein said genetic defect is β-thalassemia or sickle cell anemia.

26. Use of the demethylase of claim 1, for removing methyl groups on DNA *in vitro*.

27. Use of the demethylase of claim 1 or its cDNA of claim 2, for changing the state of differentiation of a cell to allow gene therapy, stem cell selection or cell cloning.

28. Use of the demethylase of claim 1 or its cDNA, of claim 2 for inhibiting methylation in cancer cells using vector mediated gene therapy.

29. An assay for the diagnostic of cancer in a patient, which comprises determining the level of expression of DNA demethylase of claim 1 in a sample

from said patient, wherein overexpression of said DNA demethylase is indicative of cancer cells.



$$pmC^{*}pGpmC^{*}pG \xrightarrow{\text{MNase}} mC^{*}p + Gp$$

Fig. 1A


DEAE-Sephadex A 50
Protein concentration (µg/ml)
dMTase Activity (dpm)
Relative cpm
MTase Activity(U)
Fraction Number


SP-Sepharose
Protein concentration (µg/ml)
dMTase Activity (dpm)
Fraction Number


Q-Sepharose
Protein concentration (µg/ml)
dMTase Activity (dpm)
Fraction Number


DEAE-Sephacel
Protein concentration (µg/ml)
dMTase Activity (dpm)
Fraction Number

FIG - 1B

FIG. 2A
FIG. 2B
—mdCMP
—dCMP
NM
ME
DEAE-Sephadex
S-Sepharose
Q-Sepharose
Sephacel
ddCTP
mdCTP
-RNase
Proteinase K
30 min
45 min
1 h
2 h
3 h
24 h

picomole cytosine formed
1.5
1.0
0.5
0
Volatile Assay
CpG Assay
Methyl residues removed (dpm)
4000
3000
2000
1000
0
0
50
100
150
200
Time (min.)

Fig - 2D

Methyl residues removed (dpm)
5000
4000
2000
1000
0
dMTase - + + -
ProteinaseK - + - -
RNase + + - +

Fig - 2C

NM
ME
+ dMTase
+dMTase + M. Sss1
mdCMP
dCMP
Fig - 3A
1st
2nd
meC
C
NM
ME
+ dMTase
+dMTase + M. Sss1
Fig - 3B



Labeled nucleotide:
[α32P]-dCTP

Labeled nucleotide:
[α32P]-dGTP



FIG. 3C



Fig. 4A



Fig. 4C





Fig. 4B

7/50

dAMP
mdCMP
dCMP
dTMP
dGMP
methylated
15
30
60
120
180
Nonmethylated
15
30
60
120
180
dMTase

Fig - 4D


3.962
1.234 1.155
INJECT
W1
RESET
CH3OH
4.134
1.228 1.088
INJECT
W1
RESET
14CH3OH
1.255 1.136
INJECT
W1
RESET
-dMTase
1.252 1.174
INJECT
W1
RESET
H2O
4.076
1.251 1.138
INJECT
W1
RESET
+dMTase (100µl)
+ME + CH3OH
4.087
1.252 1.057
INJECT
W1
RESET
+dMTase (100µl)
+ME
1.254 1.184
INJECT
W1
RESET
+dMTase (20µl)
+ME
1.253 1.114
INJECT
RESET
+dMTase (20µl)
+NM

FIG 4E


Toluene
Methanol
dMTase + ME-DNA
dMTase + NM-DNA
dMTase
(protease K treated)
+ ME-DNA
100
80
60
40
20
0
.90 1.00 1.10 1.20
10 20 30 40 50

Fig 4F



$$\triangle G_{Reaction} = (93) - (103 + 91.5) = (-101.5)\ Kcal$$

Fig. 5


M.MspI+M.SssI
dMTase
EcoRII
DpnI
HpaII
HhaI
MspI
nondigested
plasmid
1.00
0.71
0.49
0.40
0.32
0.24
0.15
0.45
0.57
0.40
0.39
0.27
0.34
0.10
0.33

FIG. 8A


UNTREATED
TREATED
CpG#
A T CG
A T CG
157
112
101
81
73
73
81
101
112
157
2
3

Fig 6B


A
meC
C
T
G
Time (h)
NM 0 0.5 1 2 3 18

Fig 6C


HM Control
-RNase
+RNase
Control
CpT
Control
CpA
CpG
ME
NM
mdCMP
dCMP

Fig 6D


FIG. 7B
200
Complex MW (kDa)
200
116
97
66
44
32.5
column fraction
61 62 63 64 65
mdCMP
dCMP
DNA SEQUENCE
200
116
97
66
44
32.5
21.5
FIG. 7A


Activity (dpm)
150
100
50
0
1000
100
10
669 KDa
200 KDa
150 KDa
66 KDa
0
10
20
30
40
Log (Molecular Weight)
Fraction Number

FIG - 7D


Activity (dpm)
100
75
50
25
0
1000
100
10
669 KDa
200 KDa
150 KDa
66 KDa
29 KDa
17 KDa
0
25
50
75
100
Log (Molecular Weight)
Fraction Number

FIG - 7C



FIG - 8A



homology to methylated DNA binding domain

homology to coiled coil domain

FIG - 8B


brain
heart
kidney
stomach
testis
placenta
9.0
6.0
5.0
4.0
3.0
2.5
2.0
1.5
1.0
0.5
dMTase
β–actin

Fig. 8C

Human DNA demethylase cDNA-dMTase1 and predicted amino acid sequence

5'ggggggcgtgg ccccgagaag gcggagacaa gatggccgcc catagcgctt ggaggaccta
agaggcggtg gccggggcca cgccccgggc aggagggccg ctctgtgcgc gcccgctcta
tgatgcttgc gcgcgtcccc cgcgcgccgc gctgcgggcg gggcgggtct ccgggattcc
aagggctcgg ttacggaaga agcgcagcgc cggctgggga gggggctgga tgcgcgcgca
cccgggggga ggccgctgct gcccggagca ggaggagggg gagagtgcgg cgggcggcag
cggcgctggc ggcgactccg ccatagagca gggggggccag ggcagcgcgc tcgccccgtc
cccggtgagc ggcgtgcgca gggaaggcgc tcggggcggc ggccgtggcc gggggcggtg
gaagcaggcg ggccggggcg gcggcgtctg tggccgtggc cggggccggg gccgtggccg
gggacgggga cggggccggg gccggggccg cggccgtccc ccgagtggcg gcagcggcct
tggcggcgac ggcggcggct gcggcggcgg cggcagcggt ggcggcggcg ccccccggcg
ggagccggtc cctttcccgt cggggagcgc ggggccgggg cccaggggac cccgggccac
ggagagcggg aagaggatgg attgcccggc cctccccccc ggatggaaga aggaggaagt
gatccgaaaa tctgggctaa gtgctggcaa gagcgatgtc tactacttca gtccaagtgg
taagaagttc agaagcaagc ctcagttggc aaggtacctg ggaaatactg ttgatctcag
cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaaacagag
actgcgaaac gatcctctca atcaaaataa gggtaaacca gacttgaata caacattgcc
aattagacaa acagcatcaa ttttcaaaca accggtaacc aaagtcacaa atcatcctag

FIG - 9A

taataaagtg aaatcagacc cacaacgaat gaatgaacag ccacgtcagc ttttctggga
gaagaggcta caaggactta gtgcatcaga tgtaacagaa caaattataa aaaccatgga
actacccaaa ggtcttcaag gagttggtcc aggtagcaat gatgagaccc ttttatctgc
tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt
ggaaaagaac cctgctgttt ggcttaacac atctcaaccc ctctgcaaag cttttattgt
cacagatgaa gacatcagga aacaggaaga gcgagtacag caagtacgca agaaattgga
agaagcactg atggcagaca tcttgtcgcg agctgctgat acagaagaga tggatattga
aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc
aagrgaaaat tcctagaaat tgaacaaaaa tgtttccact ggcttttgcc tgtaagaaaa
aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt tttagatgta
tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa
aattagtctt ttgtaatatc aagcaggacc ctaagatgaa gctgagcttt tgatgccagg
tgcaatctac tggaaatgta gcacttacgt aaaacatttg tttcccccac agttttaata
agaacagatc aggaattcta aataaatttc ccagttaaag attattgtga cttcactgta
tataaacata tttttatact ttattgaaag gggacacctg tacattcttc catcatcact
gtaaagacaa ataaatgatt atattcacaa aaaaaaaaaa aaaaaa 3'

SEQ ID NO:1

Fig 9B

MRAHPGGGRCCPEQEEGESAAGGSGAGGDSAIEQGGQGSALAPSPVSGVR
REGARGGGRGRGRWKQAGRGGGVCGRGRGRGRGRGRGRGRGRGRPPSG
GSGLGGDGGGCGGGGSGGGGAPRREPVPFPSGSAGPGPRGPRATESGKRM
DCPALPPGWKKEEVIRKSGLSAGKSDVYYFSPSGKKFRSKPQLARYLGNT
VDLSSFDFRTGKMMPSKLQKNKQRLRNDPLNQNKGKPDLNTTLPIRQTAS
IFKQPVTKVTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGLSASDVTEQII
KTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAV
WLNTSQPLCKAFIVTDEDIRKQEERVQQVRKKLEEALMADILSRAADTEE
MDIEMDSGDEA

SEQ ID NO:2

Fig 9C

Human DNA demethylase homologue-dMTase2 and predicted amino acid sequence

5'agcgggccga ggagccgggc gcaatggagc ggaagaggtg ggagtgcccg gcgctcccgc
agggctggga gagggaagaa gtgcccagaa ggtcggggct gtcggccggc cacagggatg
tcttttacta tagcccgagc gggaagaagt tccgcagcaa gccgcagctg gcgcgctacc
tgggcggctc catggacctg agcaccttcg acttccgcac gggcaagatg ctgatgagca
agatgaacaa gagccgccag cgcgtgcgct acgactcctc caaccaggtc aagggcaagc
ccgacctgaa cacggcgctg cccgtgcgcc agacggcgtc catcttcaag cagccggtga
ccaagattac caaccacccc agcaacaagg tcaagagcga cccgcagaag gcggtggacc
agccgcgcca gctcttctgg gagaagaagc tgagcggcct gaacgccttc gacattgctg
aggagctggt caagaccatg gacctcccca agggcctgca gggggtggga cctggctgca
cggatgagac gctgctgtcg gccatcgcca gcgccctgca cactagcacc atgcccatca
cgggacagct ctcggccgcc gtggagaaga accccggcgt atggctcaac accacgcagc
ccctgtgcaa agccttcatg gtgaccgacg aggacatcag gaagcaggaa gagctggtgc
agcaggtgcg gaagcggctg gaggaggcgc tgatggccga catgctggcg cacgtggagg
agctggcccg tgacggggag gcgccgctgg acaaggcctg cgctgaggac gacgacgagg
aagacgagga ggaggaggag gaggagcccg acccggaccc ggagatggag cacgtctagg
gcagaggccc tgccgagagc ccgtgctgcc tgctggagcc gcctgcagac gcggtcctcg
gccccacgtg aaccaggctc ggcggcgaag cccagccttg gagacaccca ggaggaaggc
cgtgctcctg gctccctcct cggcccgtcc ccacttcccg gggcctcggg gcacacagct
ggggctgccc ccacccgaaa gaccctccac gctcgtcctc tacagagtcc ggcttcggga
agtgccgggt gctcctgggc cctgcctggc tccctacgac ctttgggctc gaggccagct

Fig - 90

cctccccatg cccgctgtcc cagctccttg agactggaga gcagccagca ggtgcccggc
agctcggcgc cacggcttgc tgacagctgg gagggtttct cggtctggag gcgtagtttt
gaaactcaca tcacccactg tgcagcgtga ggacgggact ctggtctgct gtgggggca
tgcaggacgg cgccactctc tgccctgcca tgcggctggt ggtgccacag agcctcaccg
tgcctgagtg gcgtgcccag ggaggccgct ctccttcagt aaatgtaaca cagtcgaggc
acgtcatcgg gcagccttcc ctgtgtgcca acgccagcct tcgcttctga aaaccaaact
ccagccgctg ccagtcggga cttggtcgcc cggcgctgcc agaatgctcc actgccagcc
ggcccccctg cctcggtttc ccttctgttt agtggcgaca caggcaccca gctttggggt
ggtgctgacg ctcccagggg tgccaggagc cactgggaca gggtgaggct cccagacgct
cctcgaggtg cccagctctc cagggagctt ctggcccaag gcgttcttga gggatctgct
ccttaacccc ccagtgcctt ggcgagggca ggttccaagc cacagacgcc tgccccgagt
ggactttgcg gccagtccct gggtgccttc ctgggccctg cttgcccagt gagggttcct
aacgggtggg ttcawtggcc tggcccvagc gagcccccac ctgcattgac cttaggccca
tagagagggc ctgtcccggt gctgccccag ccaaggatct ggtcgctgcc ccagggggac
tgatgggcaa gagtcgcccc tgtggctgga ctgtgaccat ccctgatggg gcctgaccgc
gggagctgag gaagcgccgc tccaccgtct gccctccaag gacccgcatg gaggcagtgg
gctggcagct tcctgctgct ccctgtcaga gtcaaagcac aaatcctcag gacgggctca
agggccaggg cagccgaggg aagctccagg tggggaccac gtcttcctga ggttggtgcc
cactggctgg gaccctttgc agtggggtgg cctcccctct gtctgcctgg tggagggagc
cgtgggcgtg gggacgtgac tgaataaagc caccatgggt ggatgtgctt gg 3'

SEQ ID NO:3

FIG - 9E

MERKRWECPALPQGWEREEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQLA
RYLGGSMDLSTFDFRTGKMLMSKMNKSRQRVRYDSSNQVKGKPDLNTALP
VRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWEKKLSGLNAFD
IAEELVKTMDLPKGLQGVGPGCTDETLLSAIASALHTSTMPITGQLSAAV
EKNPGVWLNTTQPLCKAFMVTDEDIRKQEELVQQVRKRLEEALMADMLAH
VEELARDGEAPLDKACAEDDDEEDEEEEEEEPDPDPEMEHV

SEQ ID NO:4

FIG 9F

Lipman-Pearson Protein Alignment
Ktuple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>411)	Seq2(1>291)	Similarity	Gap	Gap	Consensus
human dMTase1 protein	human dMTase2 protein	Index	Number	Length	Length
(148>397)	(4>253)	76.0	0	0	250
(148>397)	(4>253)	76.0	0	0	250

```
  v150       v160       v170       v180       v190       v200       v210
KRMDCPALPPGWKKEEVIRKSGLSAGKSDVYYFSPSGKKFRSKPQLARYLGNIVDLSSFDFRTGKMMPSK
KR :CPALP.GW.:EEV R:SGLSAG..DV:Y:SPSGKKFRSKPQLARYLG.::DLS:FDFRTGKM: SK
KRWECPALPQGWEREEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQLARYLGGSMDLSIFDFRTGKMLMSK
      ^10        ^20        ^30        ^40        ^50        ^60        ^70

  v220       v230       v240       v250       v260       v270       v280
LQKNKQRLRNDPLNQNKGKPDLNTTLPIRQTASIFKQPVTKVTNHPSNKVKSDPQRMNEQPRQLFWEKRL
::K::QR:R D: NQ KGKPDLNT:LP:RQTASIFKQPVTK:TNHPSNKVKSDPQ:   :QPRQLFWEK:L
MNKSRQRVRYDSSNQVKGKPDLNTALPVRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWEKKL
      ^80        ^90        ^100       ^110       ^120       ^130       ^140
```


FIG 96

```
  v290       v300       v310       v320       v330       v340       v350
QGLSASDVTEQIIKIMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAVWLNTSQP
 GL:A D::E:::KIM:LPKGLQGVGPG..DETLLSA:ASALHTS: PITGQ:SAAVEKNP:VWLNT:QP
SGLNAFDIAEELVKIMDLPKGLQGVGPGCTDETLLSAIASALHTSTMPITGQLSAAVEKNPGVWLNTTQP
      ^150       ^160       ^170       ^180       ^190       ^200       ^210

  v360       v370       v380       v390
LCKAFIVTDEDIRKQEERVQQVRKKLEEALMADILSRAAD
LCKAF:VTDEDIRKQEE VQQVRK:LEEALMAD:L::..:
LCKAFMVTDEDIRKQEELVQQVRKRLEEALMADMLAHVEE
      ^220       ^230       ^240       ^250
```

Fig 9H

Mouse DNA demethylase-dMTase1 and predicted amino acid sequence

5' gagctatggg ggcgggggcgg gtctccgggga ttccaagggc tcggttacgg aagaagcgca
gagccggctg gggaggggggc tggatgcgcg cgcacccggg gggaggccgc tgctgcccgg
agcaggagga gggggagagc gcggcgggcg gcagcggcgc tggcggcgac tccgccatag
agcaggggggg ccagggcagc gcgctcgctc cgtccccggt gagcggcgtg cgcagggaag
gcgctcgggg cggcggccgt ggccgggggc ggtggaagca ggcggcccgg ggcggcggcg
tctgtggccg tggccgtggc cgtggccggg gtcggggccg tggccggggc cggggccggg
gccgcggccg tccccagagt ggcggcagcg gccttggcgg cgacggcggc ggcggcgcgg
gcggctgcgg cgtcggcagc ggtggcggcg tcgccccccg gcgggatcct gtccctttcc
cgtcggggag ctcggggccg gggcccaggg gaccccgggc cacggagagc gggaagagga
tggactgccc ggccctcccc cccggatgga agaaggagga agtgatccga aaatcagggc
tcagtgctgg caagagcgat gtctactact tcagtccaag tggtaagaag ttcagaagta
aacctcagct ggcaagatac ctgggaaatg ctgttgacct tagcagtttt gacttcagga
ccggcaagat gatgcctagt aaattacaga agaacaagca gagactccgg aatgaccccc
tcaatcagaa caagggtaaa ccagacctga acacaacatt gccaattaga caaactgcat
caattttcaa gcaaccagta accaaattca cgaaccaccc gagcaataag gtgaagtcag
acccccagcg gatgaatgaa caaccacgtc agcttttctg ggagaagagg ctacaaggac
ttagcgcatc agatgtaaca gaacaaatta taaaaaccat ggagctacct aaaggtcttc
aaggagtcgg tccaggtagc aatgacgaga cccttctgtc tgctgtggcc agtgctttac

27/50

FIG - 9I

acacaagctc tgcgcccatc acaggacaag tctctgctgc cgtggaaaag aaccctgctg
tttggcttaa cacatctcaa cccctctgca aagctttcat tgttacagat gaagacatta
ggaaacagga agagcgagtc caacaagtac gcaagaaact ggaggaggca ctgatggccg
acatcctgtc ccgggctgcg gacacggagg aagtagacat tgacatggac agtggagatg
aggcgtaaga atatgatcag gtaactttcg actgaccttc cccaagagca aattgctaga
aacagaatta aaacatttcc actgggtttc gcctgtaaga aaaagtgtac ctgagcacat
agctttttaa tagcactaac caatgccttt ttagatgtat ttttgatgta tatatctatt
attccaaatg atgtttattt tgaatcctag gacttaaaat gagtctttta taatagcaag
cagggccctt ccggtgcagt gcagctttga ggccaggtgc agtctactgg aaaggtagca
cttacgtgaa atatttgttt cccccacagt tttaatataa acagatcagg agtaccaaat
aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat
tgaaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat
tcac 3'

SEQ ID NO:5

Fig 9J

MRAHPGGGRCCPEQEEGESAAGGSGAGGDSAIEQGGQGSALAPSPVSGVR
REGARGGGRGRGRWKQAARGGGVCGRGRGRGRGRGRGRGRGRGRPQSG
GSGLGGDGGGGAGGCGVGSGGGVAPRRDPVPFPSGSSGPGPRGPRATESG
KRMDCPALPPGWKKEEVIRKSGLSAGKSDVYYFSPSGKKFRSKPQLARYL
GNAVDLSSFDFRTGKMMPSKLQKNKQRLRNDPLNQNKGKPDLNTTLPIRQ
TASIFKQPVTKFTNHPSNKVKSDPQRMNEQPRQLFWEKRLQGLSASDVTE
QIIKTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKN
PAVWLNTSQPLCKAFIVTDEDIRKQEERVQQVRKKLEEALMADILSRAAD
TEEVDIDMDSGDEA

SEQ ID NO:6

FIG_9K

Mouse DNA demethylase-dMTase2 and predicted amino acid sequence

```
5'cacgcgcggg cgggtgggcg gagcggcccc cctagcgggg gctgtgaagc gcggggaggg
  ggccgagcgg gtggcgaagc cggcgcgcgc ccggctgggg gcggagggcg gaggcccgtg
  ggacagaaca gctgcggcga gtggcggcgg cggagggagc cgaatcggcg acgagcccgg
  gggtcgcaac ttgcagaagc ggcggcggcg gcggcatcgg ccacggcggg cggaaaagcc
  ggggcgcaat ggagcggaag aggtgggagt gcccggcgct cccgcagggc tgggaaaggg
  aagaagtgcc caggaggtcg gggctgtcgg ccggccacag ggatgtcttt tactatagcc
  ccagcgggaa gaagttccgc agcaagccac aactggcacg ttacctgggc ggatccatgg
  acctcagcac cttcgacttc cgcaccggaa agatgttgat gaacaagatg aataagagtc
  gccagcgtgt gcgctatgat tcttccaacc aggtcaaggg caagcctgac ctgaacaccg
  cgctgcctgt acggcagact gcatccatct tcaagcaacc ggtgaccaag atcaccaacc
  accccagcaa caaggtcaag agcgacccgc agaaggcagt ggaccagccg aggcagcttt
  tctgggagaa gaagctaagt ggattgagtg cctttgacat tgcagaagaa ctggtcagga
  ccatggactt gcccaagggc ctgcagggag tgggccctgg ctgtacagat gagacgctgc
  tgtcagccat tgcgagtgct ctacacacca gcaccctgcc cattacaggc cagctctctg
  cagccgtgga gaagaaccct ggtgtgtggc tgaacactgc acagccactg tgcaaagcct
  tcatggtgac agatgacgac atcaggaagc aggaggagct ggtacagcag gtacggaagc
  gcctggagga ggcactgatg gccgacatgc tagctcatgt ggaggagctt gcccgagacg
  gggaggcacc actggacaag gcctgtgcag aggaggaaga ggaggaggaa gaggaggagg
```

FIG - 9L

aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact
gccttcagcc ttgcctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc
ctttccaaag cctcctgctt ccaggtctca gtgcagggag cccctgtgga ccttgaactc
acttgtccct gcgctgcctg gcaggaagcc ccacactgaa agcagatgag cagtgaccca
actgagaggc cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg
cttggcaccg aggagctggg agccgtgttg ggtgctggag gaagtttctg gaaacacacc
tggctatgcc caccttatgt ccctaaggct attacaggcc agggtttgga ctgctccggc
ccacagggct gcccagcctc cccacactga gggtcagcag cccaccagga agtcactttc
cttcaataaa ctgatggtag gaacttgtg 3'

SEQ ID NO:7

Fig 9M

FIG - 8N

SEQ ID NO:8

MERKRWECPALPQGWEREEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQLA
RYLGGSMDLSTFDFRTGKMLMNKMNKSRQRVRYDSSNQVKGKPDLNTALP
VRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWEKKLSGLSAFD
IAEELVRTMDLPKGLQGVGPGCTDETLLSAIASALHTSTLPITGQLSAAV
EKNPGVWLNTAQPLCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAH
VEELARDGEAPLDKACAEEEEEEEEEEPEPERV

Lipman-Pearson Protein Alignment
Ktuple: 2; Gap Penalty: 4; Gap Length Penalty: 12

Seq1(1>414)	Seq2(1>285)	Similarity	Gap	Gap	Consensus
mouse dMTase1 protein	mouse dMTase2 protein	Index	Number	Length	Length
(151>400)	(4>253)	75.2	0	0	250
(151>400)	(4>253)	75.2	0	0	250

```
        v160       v170       v180       v190       v200       v210       v220
KRMDCPALPPGWKKEEVIRKSGLSAGKSDVYYFSPSGKKFRSKPQLARYLGNAVDLSSFDFRTGKMMPSK
KR :CPALP.GW.:EEV R:SGLSAG..DV:Y:SPSGKKFRSKPQLARYLG.::DLS:FDFRTGKM: :K
KRWECPALPQGWEREEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQLARYLGGSMDLSTFDFRTGKMLMNK
      ^10        ^20        ^30        ^40        ^50        ^60        ^70

        v230       v240       v250       v260       v270       v280       v290
LQKNKQRLRNDPLNQNKGKPDLNTTLPIRQTASIFKQPVTKFTNHPSNKVKSDPQRMNEQPRQLFWEKRL
::K::QR:R D: NQ KGKPDLNT:LP:RQTASIFKQPVTK:TNHPSNKVKSDPQ:  :QPRQLFWEK:L
MNKSRQRVRYDSSNQVKGKPDLNTALPVRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWEKKL
      ^80        ^90        ^100       ^110       ^120       ^130       ^140
```

Fig 9D

```
        v300       v310       v320       v330       v340       v350       v360
QGLSASDVTEQIIKTMELPKGLQGVGPGSNDETLLSAVASALHTSSAPITGQVSAAVEKNPAVWLNTSQP
 GLSA D::E::::TM:LPKGLQGVGPG..DETLLSA:ASALHTS: PITGQ:SAAVEKNP:VWLNT:QP
SGLSAFDIAEELVRTMDLPKGLQGVGPGCTDETLLSAIASALHTSTLPITGQLSAAVEKNPGVWLNTAQP
     ^150       ^160       ^170       ^180       ^190       ^200       ^210

        v370       v380       v390       v400
LCKAFIVTDEDIRKQEERVQQVRKKLEEALMADILSRAAD
LCKAF:VTD:DIRKQEE VQQVRK:LEEALMAD:L::..:
LCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAHVEE
     ^220       ^230       ^240       ^250
```

Fig 9P


Not 1
MDBD
1.36 kb
Not 1
ATG
(His)6
Xpress
EK
MCS
BGHpA
T7
PCMV
pcDNA-His-dMTase


66
45
29
mistranne
dMTase

FIG-10A


500
400
300
200
100
0
volatilized methyl residues (dpm)
50 200 350 500 700 1000
imidazole concentration (mM)
dMTase
misframe

Fig. 10B

volatilized methyl residues (dpm)
400
300
200
100
0
0 1 3 10 10+ Protease K
IMAC purified DNA dMTase (µl)
FIG. 10C
dMTase
mistrame
—mdCMP
—dCMP
(mdCpdG)n
NM
Time (min)
0
15
30
60
120
180
mdCMP—
dCMP—
Substrate:
pBluescript SK+
FIG. 10D


500
400
300
200
100
0
non transfected
dMTase
misframe
volatilized methyl residues (dpm)
50
200
350
500
700
1000
imidazole concentration (mM)

Fig. 11A

11E
me SK + Hpa II
dMTase
Buffer L
dMTase+
Protease K
0.71
0.49, 0.40
0.32
0.24
0.15
11D
dMTase
NM
ME
mdCMP
dCMP
pBluescript
SK+
substrate
(mdCpdG)n
11C
NM
ME
dMTase
mistranme
dMTase
+ Protease K
11B
dMTase
empty
vector
250
148
60
42
30


300
250
200
150
100
50
0
Velocity (pmol/h)
0
10
20
30
40
[Substrate: (mdCpdG)n] (nM)

Fig. 11F

methylated CpG DNA (ng)
1
10
50
100
– mdCMP
– dCMP
– Origin
A549 dMTase
Transient dMTase

Fig. 12A

FIG -12B


in vitro dMTase misframe
Transient dMTase
Transient dMTase misframe
Toluene
Methanol
in vitro dMTase
100
80
60
40
20
0
10
20
30
40
50





Fig-13A



Fig-13B


1500
1000
500
0
volatilized methyl residues (dpm)
Muscle
Kidney
Brain
Heart
Spleen
Liver
P19
P19 ras
Y1
A549
Control

FIG. 13C


brain
heart
kidney
stomach
testis
liver
spleen
Y1
dMTase
~1.5 kb
18s


dMTase / 18s
0.020
0.016
0.012
0.008
0.004
0.000
brain
heart
kidney
stomach
testis
liver
spleen
Y1

FIG 13D

FIG - 14A


pRetro-On 6.8 kb
Ampr
5' LTR
ψ+
Puror
PSV40
rtTA
PminCMV
TRE
3' LTR
EcoRI
HindIII
XhoI MCS
Not 1
demethylase cDNA
Not 1
ATG
(His)6
Anti-Xpress Im Epitope
EK Site
Asp718I
KpnI
BamH I
BsiX I
EcoR I
EcoR V
BsiX I
NotI
XhoI
XhaI
T7
BGHpA
11ori
SV40ori
Neomycin
SV40pA
ColE1
pcDNA3.1/ His A,B,C 5.5kb
Pcmv
Ampicillin
pTriplEx 3570 bp
pUC ori
Ampr
Ploc
Lac2'
f1 ori
LaxP
NheI (266)
EcoR V(312)
MunI(431)
BglII(495)
MCS* (529-636)
NaeI(1153)
ClaI(1338)
ClaI(1380)
Eco0109I(1577)
AatII (1638)
XmnI (1957)
AflIII (3445)
AlwN I (3036)



Fig - 14B



Fig - 14C


Average number of colonies per well
175
150
125
100
75
50
25
0
pRetro ON [No Dox]
pRetro ON [Dox]
pRetro-Sense [No Dox]
pRetro-Sense [Dox]
pRetro-Antisense [No Dox]
pRetro-Antisense [Dox]


Antisense
COILED-COIL
MDBD
Not 1
Not 1
Sense
MDBD
COILED-COIL
1.36 kb
TRE
PCMV
MCS
3'MoMuLVLTR
pRetro-ON dMTase

Fig. 15


Volatile methyl residue (dpm)
4000
3000
2000
1000
0
0
1
10
100
1000
10000
Concentration of imidazole (μM)

Fig. 16


cancer signals
MeTase
MeTase
MeTase
Death
deMeTase
inhibitor of deMeTase

Fig - 17

SEQUENCE LISTING

<110> McGILL UNIVERSITY
SZYF, Moshe
BHATTACHARYA, Sanjoy K.
RAMCHANDANI, Shyam

<120> DNA DEMETHYLASE, THERAPEUTIC AND DIAGNOSTIC USES THEREOF

<130> 1770-183"PCT" FC/ld

<150> CA 2,220,805
<151> 1997-11-12

<150> CA 2,230,991
<151> 1998-05-11

<160> 10

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 1804
<212> DNA
<213> Unknown

<400> 1

ccgctctgcg ggcggggcgg gtctccggga ttccaagggc tcggttacgg aagaagcgca 60
gagccggctg gggagggggc tggatgcgcg cgcacccggg gggaggccgc tgctgcccgg 120
agcaggagga gggggagagc gcggcgggcg gcagcggcgc tggcggcgac tccgccatag 180
agcaggggg ccagggcagc gcgctcgctc cgtccccggt gagcggcgtg cgcagggaag 240
gcgctcgggg cggcggccgt ggccgggggc ggtggaagca ggcggcccgg ggcggcggcg 300
tctgtggccg tggccgtggc cgtggccggg gtcggggccg tggccggggc cggggccggg 360
gccgcggccg tccccagagt ggcggcagcg gccttggcgg cgacggcggc ggcggcgcgg 420
gcggctgcgg cgtcggcagc ggtggcggcg tcgccccccg gcgggatcct gtccctttcc 480
cgtcggggag ctcggggccg gggcccaggg gaccccgggc cacggagagc gggaagagga 540
tggactgccc ggccctcccc cccggatgga agaaggagga agtgatccga aaatcagggc 600
tcagtgctgg caagagcgat gtctactact tcagtccaag tggtaagaag ttcagaagta 660
aacctcagct ggcaagatac ctgggaaatg ctgttgacct tagcagtttt gacttcagga 720
ccggcaagat gatgcctagt aaattacaga agaacaagca gagactccgg aatgaccccc 780
tcaatcagaa caagggtaaa ccagacctga acacaacatt gccaattaga caaactgcat 840
caattttcaa gcaaccagta accaaattca cgaaccaccc gagcaataag gtgaagtcag 900
acccccagcg gatgaatgaa caaccacgtc agcttttctg ggagaagagg ctacaaggac 960
ttagcgcatc agatgtaaca gaacaaatta taaaaaccat ggagctacct aaaggtcttc 1020
aaggagtcgg tccaggtagc aatgacgaga cccttctgtc tgctgtggcc agtgctttac 1080
acacaagctc tgcgcccatc acaggacaag tctctgctgc cgtggaaaag aaccctgctg 1140
tttggcttaa cacatctcaa cccctctgca aagctttcat tgttacagat gaagacatta 1200
ggaaacagga agagcgagtc caacaagtac gcaagaaact ggaggaggca ctgatggccg 1260
acatcctgtc ccgggctgcg gacacggagg aagtagacat tgacatggac agtggagatg 1320
aggcgtaaga atatgatcag gtaactttcg actgaccttc cccaagagca aattgctaga 1380
aacagaatta aaacatttcc actgggtttc gcctgtaaga aaaagtgtac ctgagcacat 1440
agcttttaa tagcactaac caatgccttt ttagatgtat ttttgatgta tatatctatt 1500
attccaaatg atgtttattt tgaatcctag gacttaaaat gagtctttta taatagcaag 1560
cagggccctt ccggtgcagt gcagctttga ggccaggtgc agtctactgg aaaggtagca 1620
cttacgtgaa atatttgttt cccccacagt tttaatataa acagatcagg agtaccaaat 1680

aagtttccca attaaagatt attatacttc actgtatata aacagatttt tatactttat 1740
tgaaagaaga tacctgtaca ttcttccatc atcactgtaa agacaaataa atgactatat 1800
tcac 1804

<210> 2
<211> 411
<212> PRT
<213> Unknown

<400> 2

```
Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu
 1               5                  10                  15
Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile
            20                  25                  30
Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly
        35                  40                  45
Val Arg Arg Glu Gly Ala Arg Gly Gly Gly Arg Gly Arg Gly Arg Trp
    50                  55                  60
Lys Gln Ala Gly Arg Gly Gly Gly Val Cys Gly Arg Gly Arg Gly Arg
65                  70                  75                  80
Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
                85                  90                  95
Pro Pro Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Cys Gly
            100                 105                 110
Gly Gly Gly Ser Gly Gly Gly Gly Ala Pro Arg Arg Glu Pro Val Pro
        115                 120                 125
Phe Pro Ser Gly Ser Ala Gly Pro Gly Pro Arg Gly Pro Arg Ala Thr
    130                 135                 140
Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro Gly Trp Lys
145                 150                 155                 160
Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly Lys Ser Asp
                165                 170                 175
Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln
            180                 185                 190
Leu Ala Arg Tyr Leu Gly Asn Thr Val Asp Leu Ser Ser Phe Asp Phe
        195                 200                 205
Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn Lys Gln Arg
    210                 215                 220
Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro Asp Leu Asn
225                 230                 235                 240
Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val
                245                 250                 255
Thr Lys Val Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln
            260                 265                 270
Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys Arg Leu Gln
        275                 280                 285
Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys Thr Met Glu
    290                 295                 300
Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn Asp Glu Thr
305                 310                 315                 320
Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser Ala Pro Ile
                325                 330                 335
Thr Gly Gln Val Ser Ala Ala Val Glu Lys Asn Pro Ala Val Trp Leu
            340                 345                 350
Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr Asp Glu Asp
        355                 360                 365
```

```
Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys Lys Leu Glu
    370                 375                 380
Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp Thr Glu Glu
385                 390                 395                 400
Met Asp Ile Glu Met Asp Ser Gly Asp Glu Ala
                405                 410
```

<210> 3
<211> 1589
<212> DNA
<213> Unknown

<400> 3

```
cacgcgcggg cgggtgggcg gagcggcccc cctagcgggg gctgtgaagc gcggggaggg    60
ggccgagcgg gtggcgaagc cggcgcgcgc ccggctgggg gcggagggcg gaggcccgtg   120
ggacagaaca gctgcggcga gtggcggcgg cggagggagc cgaatcggcg acgagcccgg   180
gggtcgcaac ttgcagaagc ggcggcggcg gcggcatcgg ccacggcggg cggaaaagcc   240
ggggcgcaat ggagcggaag aggtgggagt gcccggcgct cccgcagggc tgggaaaggg   300
aagaagtgcc caggaggtcg gggctgtcgg ccggccacag ggatgtcttt tactatagcc   360
ccagcgggaa gaagttccgc agcaagccac aactggcacg ttacctgggc ggatccatgg   420
acctcagcac cttcgacttc cgcaccggaa agatgttgat gaacaagatg aataagagtc   480
gccagcgtgt gcgctatgat tcttccaacc aggtcaaggg caagcctgac ctgaacaccg   540
cgctgcctgt acggcagact gcatccatct tcaagcaacc ggtgaccaag atcaccaacc   600
accccagcaa caaggtcaag agcgacccgc agaaggcagt ggaccagccg aggcagcttt   660
tctgggagaa gaagctaagt ggattgagtg cctttgacat tgcagaagaa ctggtcagga   720
ccatggactt gcccaagggc ctgcagggag tgggccctgg ctgtacagat gagacgctgc   780
tgtcagccat tgcgagtgct ctacacacca gcaccctgcc cattacaggc cagctctctg   840
cagccgtgga gaagaaccct ggtgtgtggc tgaacactgc acagccactg tgcaaagcct   900
tcatggtgac agatgacgac atcaggaagc aggaggagct ggtacagcag gtacggaagc   960
gcctggagga ggcactgatg gccgacatgc tagctcatgt ggaggagctt gcccgagacg  1020
gggaggcacc actggacaag gcctgtgcag aggaggaaga ggaggaggaa gaggaggagg  1080
aagagccgga gccagagcga gtgtagcaca ggtgccctgc ccaagtctgg gctgcagact  1140
gccttcagcc ttgcctggac caggtagggg ccagacctgt aggaggcagc cgtccacctc  1200
ctttccaaag cctcctgctt ccaggtctca gtgcagggag cccctgtgga ccttgaactc  1260
acttgtccct gcgctgcctg gcaggaagcc ccacactgaa agcagatgag cagtgaccca  1320
actgagaggc cacctggaca cagtcacctc cctgcctcct tatcatagga caaggccttg  1380
cttggcaccg aggagctggg agccgtgttg ggtgctggag gaagtttctg gaaacacacc  1440
tggctatgcc caccttatgt ccctaaggct attacaggcc agggtttgga ctgctccggc  1500
ccacagggct gcccagcctc cccacactga gggtcagcag cccaccagga agtcactttc  1560
cttcaataaa ctgatggtag gaacttgtg                                    1589
```

<210> 4
<211> 291
<212> PRT
<213> Unknown

<400> 4

```
Met Glu Arg Lys Arg Trp Glu Cys Pro Ala Leu Pro Gln Gly Trp Glu
 1               5                  10                  15
Arg Glu Glu Val Pro Arg Arg Ser Gly Leu Ser Ala Gly His Arg Asp
            20                  25                  30
Val Phe Tyr Tyr Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln
        35                  40                  45
Leu Ala Arg Tyr Leu Gly Gly Ser Met Asp Leu Ser Thr Phe Asp Phe
    50                  55                  60
Arg Thr Gly Lys Met Leu Met Ser Lys Met Asn Lys Ser Arg Gln Arg
65                  70                  75                  80
```

```
Val Arg Tyr Asp Ser Ser Asn Gln Val Lys Gly Lys Pro Asp Leu Asn
                85                  90                  95
Thr Ala Leu Pro Val Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val
            100                 105                 110
Thr Lys Ile Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln
        115                 120                 125
Lys Ala Val Asp Gln Pro Arg Gln Leu Phe Trp Glu Lys Lys Leu Ser
    130                 135                 140
Gly Leu Asn Ala Phe Asp Ile Ala Glu Glu Leu Val Lys Thr Met Asp
145                 150                 155                 160
Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Cys Thr Asp Glu Thr
                165                 170                 175
Leu Leu Ser Ala Ile Ala Ser Ala Leu His Thr Ser Thr Met Pro Ile
            180                 185                 190
Thr Gly Gln Leu Ser Ala Ala Val Glu Lys Asn Pro Gly Val Trp Leu
        195                 200                 205
Asn Thr Thr Gln Pro Leu Cys Lys Ala Phe Met Val Thr Asp Glu Asp
    210                 215                 220
Ile Arg Lys Gln Glu Glu Leu Val Gln Gln Val Arg Lys Arg Leu Glu
225                 230                 235                 240
Glu Ala Leu Met Ala Asp Met Leu Ala His Val Glu Glu Leu Ala Arg
                245                 250                 255
Asp Gly Glu Ala Pro Leu Asp Lys Ala Cys Ala Glu Asp Asp Asp Glu
            260                 265                 270
Glu Asp Glu Glu Glu Glu Glu Glu Glu Pro Asp Pro Asp Pro Glu Met
        275                 280                 285
Glu His Val
    290
```

<210> 5
<211> 1966
<212> DNA
<213> Unknown

<400> 5

```
gggggcgtgg ccccgagaag gcggagacaa gatggccgcc catagcgctt ggaggaccta    60
agaggcggtg gccggggcca cgccccgggc aggagggccg ctctgtgcgc gcccgctcta   120
tgatgcttgc gcgcgtcccc cgcgcgccgc gctgcgggcg gggcgggtct ccgggattcc   180
aagggctcgg ttacggaaga agcgcagcgc cggctgggga gggggctgga tgcgcgcgca   240
cccgggggga ggccgctgct gcccggagca ggaggagggg gagagtgcgg cgggcggcag   300
cggcgctggc ggcgactccg ccatagagca gggggggccag ggcagcgcgc tcgccccgtc  360
cccggtgagc ggcgtgcgca gggaaggcgc tcggggcggc ggccgtggcc gggggcggtg   420
gaagcaggcg ggccggggcg gcggcgtctg tggccgtggc cggggccggg gccgtggccg   480
gggacgggga cggggccggg gccggggccg cggccgtccc ccgagtggcg gcagcggcct   540
tggcggcgac ggcggcggct gcggcggcgg cggcagcggt ggcggcggcg ccccccggcg   600
ggagccggtc cctttcccgt cggggagcgc ggggccgggg cccaggggac cccgggccac   660
ggagagcggg aagaggatgg attgcccggc cctccccccc ggatggaaga aggaggaagt   720
gatccgaaaa tctgggctaa gtgctggcaa gagcgatgtc tactacttca gtccaagtgg   780
taagaagttc agaagcaagc ctcagttggc aaggtacctg ggaaatactg ttgatctcag   840
cagttttgac ttcagaactg gaaagatgat gcctagtaaa ttacagaaga acaaacagag   900
actgcgaaac gatcctctca atcaaaataa gggtaaacca gacttgaata caacattgcc   960
aattagacaa acagcatcaa ttttcaaaca accggtaacc aaagtcacaa atcatcctag  1020
taataaagtg aaatcagacc cacaacgaat gaatgaacag ccacgtcagc ttttctggga  1080
gaagaggcta caaggactta gtgcatcaga tgtaacagaa caaattataa aaaccatgga  1140
actacccaaa ggtcttcaag gagttggtcc aggtagcaat gatgagaccc ttttatctgc  1200
tgttgccagt gctttgcaca caagctctgc gccaatcaca gggcaagtct ccgctgctgt  1260
ggaaaagaac cctgctgttt ggcttaacac atctcaaccc ctctgcaaag cttttattgt  1320
```

cacagatgaa gacatcagga aacaggaaga gcgagtacag caagtacgca agaaattgga 1380
agaagcactg atggcagaca tcttgtcgcg agctgctgat acagaagaga tggatattga 1440
aatggacagt ggagatgaag cctaagaata tgatcaggta actttcgacc gactttcccc 1500
aagrgaaaat tcctagaaat tgaacaaaaa tgtttccact ggcttttgcc tgtaagaaaa 1560
aaaatgtacc cgagcacata gagcttttta atagcactaa ccaatgcctt tttagatgta 1620
tttttgatgt atatatctat tattcaaaaa atcatgttta ttttgagtcc taggacttaa 1680
aattagtctt ttgtaatatc aagcaggacc ctaagatgaa gctgagcttt tgatgccagg 1740
tgcaatctac tggaaatgta gcacttacgt aaaacatttg tttcccccac agttttaata 1800
agaacagatc aggaattcta aataaatttc ccagttaaag attattgtga cttcactgta 1860
tataaacata tttttatact ttattgaaag gggacacctg tacattcttc catcatcact 1920
gtaaagacaa ataaatgatt atattcacaa aaaaaaaaaa aaaaaa 1966

<210> 6
<211> 414
<212> PRT
<213> Unknown

<400> 6

```
Met Arg Ala His Pro Gly Gly Gly Arg Cys Cys Pro Glu Gln Glu Glu
 1               5                  10                  15
Gly Glu Ser Ala Ala Gly Gly Ser Gly Ala Gly Gly Asp Ser Ala Ile
            20                  25                  30
Glu Gln Gly Gly Gln Gly Ser Ala Leu Ala Pro Ser Pro Val Ser Gly
        35                  40                  45
Val Arg Arg Glu Gly Ala Arg Gly Gly Gly Arg Gly Arg Gly Arg Trp
    50                  55                  60
Lys Gln Ala Ala Arg Gly Gly Gly Val Cys Gly Arg Gly Arg Gly Arg
65                  70                  75                  80
Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg Gly Arg
                85                  90                  95
Pro Gln Ser Gly Gly Ser Gly Leu Gly Gly Asp Gly Gly Gly Gly Ala
            100                 105                 110
Gly Gly Cys Gly Val Gly Ser Gly Gly Gly Val Ala Pro Arg Arg Asp
        115                 120                 125
Pro Val Pro Phe Pro Ser Gly Ser Ser Gly Pro Gly Pro Arg Gly Pro
    130                 135                 140
Arg Ala Thr Glu Ser Gly Lys Arg Met Asp Cys Pro Ala Leu Pro Pro
145                 150                 155                 160
Gly Trp Lys Lys Glu Glu Val Ile Arg Lys Ser Gly Leu Ser Ala Gly
                165                 170                 175
Lys Ser Asp Val Tyr Tyr Phe Ser Pro Ser Gly Lys Lys Phe Arg Ser
            180                 185                 190
Lys Pro Gln Leu Ala Arg Tyr Leu Gly Asn Ala Val Asp Leu Ser Ser
        195                 200                 205
Phe Asp Phe Arg Thr Gly Lys Met Met Pro Ser Lys Leu Gln Lys Asn
    210                 215                 220
Lys Gln Arg Leu Arg Asn Asp Pro Leu Asn Gln Asn Lys Gly Lys Pro
225                 230                 235                 240
Asp Leu Asn Thr Thr Leu Pro Ile Arg Gln Thr Ala Ser Ile Phe Lys
                245                 250                 255
Gln Pro Val Thr Lys Phe Thr Asn His Pro Ser Asn Lys Val Lys Ser
            260                 265                 270
Asp Pro Gln Arg Met Asn Glu Gln Pro Arg Gln Leu Phe Trp Glu Lys
        275                 280                 285
Arg Leu Gln Gly Leu Ser Ala Ser Asp Val Thr Glu Gln Ile Ile Lys
    290                 295                 300
```

```
Thr Met Glu Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Ser Asn
305                 310                 315                 320
Asp Glu Thr Leu Leu Ser Ala Val Ala Ser Ala Leu His Thr Ser Ser
                325                 330                 335
Ala Pro Ile Thr Gly Gln Val Ser Ala Ala Val Glu Lys Asn Pro Ala
            340                 345                 350
Val Trp Leu Asn Thr Ser Gln Pro Leu Cys Lys Ala Phe Ile Val Thr
        355                 360                 365
Asp Glu Asp Ile Arg Lys Gln Glu Glu Arg Val Gln Gln Val Arg Lys
    370                 375                 380
Lys Leu Glu Glu Ala Leu Met Ala Asp Ile Leu Ser Arg Ala Ala Asp
385                 390                 395                 400
Thr Glu Glu Val Asp Ile Asp Met Asp Ser Gly Asp Glu Ala
                405                 410
```

<210> 7
<211> 2392
<212> DNA
<213> Unknown

<400> 7

```
agcgggccga ggagccgggc gcaatggagc ggaagaggtg ggagtgcccg gcgctcccgc    60
agggctggga gagggaagaa gtgcccagaa ggtcggggct gtcggccggc cacagggatg   120
tcttttacta tagcccgagc gggaagaagt tccgcagcaa gccgcagctg gcgcgctacc   180
tgggcggctc catggacctg agcaccttcg acttccgcac gggcaagatg ctgatgagca   240
agatgaacaa gagccgccag cgcgtgcgct acgactcctc caaccaggtc aagggcaagc   300
ccgacctgaa cacggcgctg cccgtgcgcc agacggcgtc catcttcaag cagccggtga   360
ccaagattac caaccacccc agcaacaagg tcaagagcga cccgcagaag gcggtggacc   420
agccgcgcca gctcttctgg gagaagaagc tgagcggcct gaacgccttc gacattgctg   480
aggagctggt caagaccatg gacctcccca agggcctgca gggggtggga cctggctgca   540
cggatgagac gctgctgtcg gccatcgcca gcgccctgca cactagcacc atgcccatca   600
cgggacagct ctcggccgcc gtggagaaga accccggcgt atggctcaac accacgcagc   660
ccctgtgcaa agccttcatg gtgaccgacg aggacatcag gaagcaggaa gagctggtgc   720
agcaggtgcg gaagcggctg gaggaggcgc tgatggccga catgctggcg cacgtggagg   780
agctggcccg tgacggggag gcgccgctgg acaaggcctg cgctgaggac gacgacgagg   840
aagacgagga ggaggaggag gaggagcccg acccggaccc ggagatggag cacgtctagg   900
gcagaggccc tgccgagagc ccgtgctgcc tgctggagcc gcctgcagac gcggtcctcg   960
gccccacgtg aaccaggctc ggcggcgaag cccagccttg gagacaccca ggaggaaggc  1020
cgtgctcctg gctccctcct cggcccgtcc ccacttcccg gggcctcggg gcacacagct  1080
ggggctgccc ccacccgaaa gaccctccac gctcgtcctc tacagagtcc ggcttcggga  1140
agtgccgggt gctcctgggc cctgcctggc tccctacgac ctttgggctc gaggccagct  1200
cctccccatg cccgctgtcc cagctccttg agactggaga gcagccagca ggtgcccggc  1260
agctcggcgc cacggcttgc tgacagctgg gagggtttct cggtctggag gcgtagtttt  1320
gaaactcaca tcacccactg tgcagcgtga ggacgggact ctggtctgct gtgggggggca  1380
tgcaggacgg cgccactctc tgccctgcca tgcggctggt ggtgccacag agcctcaccg  1440
tgcctgagtg gcgtgcccag ggaggccgct ctccttcagt aaatgtaaca cagtcgaggc  1500
acgtcatcgg gcagccttcc ctgtgtgcca acgccagcct tcgcttctga aaaccaaact  1560
ccagccgctg ccagtcggga cttggtcgcc cggcgctgcc agaatgctcc actgccagcc  1620
ggcccccctg cctcggtttc ccttctgttt agtggcgaca caggcaccca gctttggggt  1680
ggtgctgacg ctcccagggg tgccaggagc cactgggaca gggtgaggct cccagacgct  1740
cctcgaggtg cccagctctc cagggagctt ctggcccaag gcgttcttga gggatctgct  1800
ccttaacccc ccagtgcctt ggcgagggca ggttccaagc cacagacgcc tgccccgagt  1860
ggactttgcg gccagtccct gggtgccttc ctgggccctg cttgcccagt gagggttcct  1920
aacgggtggg ttcawtggcc tggcccvagc gagcccccac ctgcattgac cttaggccca  1980
tagagagggc ctgtcccggt gctgccccag ccaaggatct ggtcgctgcc ccaggggggac  2040
tgatgggcaa gagtcgcccc tgtggctgga ctgtgaccat ccctgatggg gcctgaccgc  2100
gggagctgag gaagcgccgc tccaccgtct gccctccaag gacccgcatg gaggcagtgg  2160
```

gctggcagct tcctgctgct ccctgtcaga gtcaaagcac aaatcctcag gacgggctca 2220
agggccaggg cagccgaggg aagctccagg tggggaccac gtcttcctga ggttggtgcc 2280
cactggctgg gacccttttgc agtggggtgg cctcccctct gtctgcctgg tggagggagc 2340
cgtgggcgtg gggacgtgac tgaataaagc caccatgggt ggatgtgctt gg 2392

<210> 8
<211> 285
<212> PRT
<213> Unknown

<400> 8

```
Met Glu Arg Lys Arg Trp Glu Cys Pro Ala Leu Pro Gln Gly Trp Glu
 1               5                  10                  15
Arg Glu Glu Val Pro Arg Arg Ser Gly Leu Ser Ala Gly His Arg Asp
            20                  25                  30
Val Phe Tyr Tyr Ser Pro Ser Gly Lys Lys Phe Arg Ser Lys Pro Gln
        35                  40                  45
Leu Ala Arg Tyr Leu Gly Gly Ser Met Asp Leu Ser Thr Phe Asp Phe
    50                  55                  60
Arg Thr Gly Lys Met Leu Met Asn Lys Met Asn Lys Ser Arg Gln Arg
65                  70                  75                  80
Val Arg Tyr Asp Ser Ser Asn Gln Val Lys Gly Lys Pro Asp Leu Asn
                85                  90                  95
Thr Ala Leu Pro Val Arg Gln Thr Ala Ser Ile Phe Lys Gln Pro Val
            100                 105                 110
Thr Lys Ile Thr Asn His Pro Ser Asn Lys Val Lys Ser Asp Pro Gln
        115                 120                 125
Lys Ala Val Asp Gln Pro Arg Gln Leu Phe Trp Glu Lys Lys Leu Ser
    130                 135                 140
Gly Leu Ser Ala Phe Asp Ile Ala Glu Glu Leu Val Arg Thr Met Asp
145                 150                 155                 160
Leu Pro Lys Gly Leu Gln Gly Val Gly Pro Gly Cys Thr Asp Glu Thr
                165                 170                 175
Leu Leu Ser Ala Ile Ala Ser Ala Leu His Thr Ser Thr Leu Pro Ile
            180                 185                 190
Thr Gly Gln Leu Ser Ala Ala Val Glu Lys Asn Pro Gly Val Trp Leu
        195                 200                 205
Asn Thr Ala Gln Pro Leu Cys Lys Ala Phe Met Val Thr Asp Asp Asp
    210                 215                 220
Ile Arg Lys Gln Glu Glu Leu Val Gln Gln Val Arg Lys Arg Leu Glu
225                 230                 235                 240
Glu Ala Leu Met Ala Asp Met Leu Ala His Val Glu Glu Leu Ala Arg
                245                 250                 255
Asp Gly Glu Ala Pro Leu Asp Lys Ala Cys Ala Glu Glu Glu Glu Glu
            260                 265                 270
Glu Glu Glu Glu Glu Glu Glu Pro Glu Pro Glu Arg Val
        275                 280                 285
```

<210> 9
<211> 17
<212> DNA
<213> Unknown

<400> 9
ctggcaagag cgatgtc

<210> 10
<211> 22
<212> DNA
<213> Unknown

<400> 10
agtctggttt acccttattt tg 22

INTERNATIONAL SEARCH REPORT

national Application No
PCT/CA 98/01059

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/52 C12N9/00 A61K38/43 C07K16/40 C12N15/11
A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	BHATTTACHARYA SK ET AL: "A mammalian protein with specific demethylase activity for mCpG DNA" NATURE, vol. 397, 18 February 1999, pages 579-583, XP002097746 LONDON GB ---	
P,X	HENDRICH B ET AL: "Identification and characterization of a family of mammalian methyl-CpG binding proteins." MOLECULAR AND CELLULAR BIOLOGY, (1998 NOV) 18 (11) 6538-47. JOURNAL CODE: NGY. ISSN: 0270-7306., XP002097747 United States see the whole document --- -/--	1-3

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 March 1999	08/04/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Espen, J

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

:national Application No
PCT/CA 98/01059

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SZYF M. ET AL.: "Mammalian cells contain a general (CpG) DNA demethylating activity" MOLECULAR BIOLOGY OF THE CELL, vol. 4, October 1993, page 74A XP002087767 * abstract 426 *	1
X	SZYF M ET AL: "Ras induces a general DNA demethylation activity in mouse embryonal P19 cells." J BIOL CHEM, MAY 26 1995, 270 (21) P12690-6, XP002087765 UNITED STATES see the whole document	1
X	SZYF M: "DNA methylation properties: consequences for pharmacology." TRENDS PHARMACOL SCI, JUL 1994, 15 (7) P233-8, XP002087766 ENGLAND see page 234, right-hand column; figures 1,2	1
X	WEISS A ET AL: "The role of DNA demethylation during development." GENES TO CELLS, (1997 AUG) 2 (8) 481-6. REF: 35 JOURNAL CODE: CUF. ISSN: 1356-9597., XP002097748 ENGLAND: United Kingdom see figures 3,4	1
X	WEISS A ET AL: "DNA demethylation in vitro: involvement of RNA" CELL, vol. 86, 1996, pages 709-718, XP002097749 NA US see the whole document	1
X	WO 95 15373 A (UNIV MCGILL ;SZYF MOSHE (CA)) 8 June 1995 see claims 12,13	1

2

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 98/ 01059

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

See continuation sheet

2. [X] Claims Nos.: 19:22 (in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Said claims relate to antagonists, inhibitors or small molecules without giving a true technical characterization of the claimed matter. In consequence, the scope of said claims is ambiguous and, moreover, their subject-matter is vague and not sufficiently disclosed.

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment).
Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

·national Application No
PCT/CA 98/01059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515373 A	08-06-1995	CA 2110213 A	31-05-1995
		AU 1061395 A	19-06-1995
		CA 2177031 A	08-06-1995
		EP 0734436 A	02-10-1996
		EP 0889122 A	07-01-1999
		JP 9506253 T	24-06-1997

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
1770-183PCT		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/CA98/01059	12/11/1998	12/11/1997

International Patent Classification (IPC) or national classification and IPC
C12N15/52

Applicant
McGILL UNIVERSITY et al.

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☒ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
07/06/1999	10.02.00

Name and mailing address of the international preliminary examining authority:
European Patent Office - P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk - Pays Bas

Authorized officer
Espen I

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/01059

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-44	as originally filed				

Claims, No.:

9-29	as originally filed				
1-8	as received on	09/12/1999	with letter of	09/12/1999	

Drawings, sheets:

1/36-36/36	as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

   - ☐ copy of the earlier application whose priority has been claimed.
   - ☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 19, in part: 22.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item II

Priority

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.
In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.
Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).
This also applies for the claims referring to or depending on said claims 2 and 3.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

D1: MOLECULAR AND CELLULAR BIOLOGY, vol. 18, pp. 6538-6547, November 11, 1998
D2: nucleotide accession number AF072242; 28 Oct 1998
D3: nucleotide accession number AF072243; 28 Oct 1998
D4 : nucleotide accession number AF072247, 28 Oct 1998
D5: nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to Mus musculus methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to Homo sapiens methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to Homo sapiens methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:
Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).
In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.
Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.
D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as the relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3; in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

Re Item VIII

Certain observations on the international application

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.
Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.
Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.
Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, their exists an inconsistency not allowable under Art. 6 PCT.

PATENT COOPERATION TREATY

09/554414

PCT

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

COTE, F.
SWABEY OGILVY RENAULT
1981 McGill College Avenue
Suite 1600
Montréal, Québec H3A 2Y3
CANADA

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Rule 71.1)

Date of mailing *(day/month/year)*	10.02.00
Applicant's or agent's file reference 1770-183PCT	IMPORTANT NOTIFICATION

International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/CA98/01059	12/11/1998	12/11/1997

Applicant
McGILL UNIVERSITY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.

2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.

3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Sinanovic, E Tel.+31 70 340-3596

Form PCT/IPEA/416 (July 1992)

PATENT COOPERATION TREATY

PCT

09/554414

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
1770-183PCT		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/CA98/01059	12/11/1998	12/11/1997
International Patent Classification (IPC) or national classification and IPC		
C12N15/52		
Applicant		
McGILL UNIVERSITY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☒ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
07/06/1999	10.02.00
Name and mailing address of the international preliminary examining authority:	Authorized officer
European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Espen, J Telephone No. +31 70 340 2625

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/01059

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-44	as originally filed				

Claims, No.:

9-29	as originally filed				
1-8	as received on	09/12/1999	with letter of	09/12/1999	

Drawings, sheets:

1/36-36/36	as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 19, in part: 22.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item II
Priority

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.
In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.
Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).
This also applies for the claims referring to or depending on said claims 2 and 3.

Re Item III
Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

D1: MOLECULAR AND CELLULAR BIOLOGY, vol. 18, pp. 6538-6547, November 11, 1998
D2: nucleotide accession number AF072242; 28 Oct 1998
D3: nucleotide accession number AF072243; 28 Oct 1998
D4 : nucleotide accession number AF072247, 28 Oct 1998
D5: nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to Mus musculus methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to Homo sapiens methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to Homo sapiens methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:
Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).
In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.
Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.
D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as the relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3, in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

Re Item VIII

Certain observations on the international application

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.
Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.
Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.
Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, their exists an inconsistency not allowable under Art. 6 PCT.

PATENT COOPERATION TREATY

PCT

09/554414

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
1770-183PCT		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/CA 98/ 01059	12/11/1998	12/11/1997
Applicant		
McGILL UNIVERSITY et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

[ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

[X] contained in the international application in written form.

[X] filed together with the international application in computer readable form.

[ ] furnished subsequently to this Authority in written form.

[ ] furnished subsequently to this Authority in computer readble form.

[ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

[ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

[X] the text is approved as submitted by the applicant.

[ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

[X] the text is approved as submitted by the applicant.

[ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. –

[ ] as suggested by the applicant.

[ ] because the applicant failed to suggest a figure.

[ ] because this figure better characterizes the invention.

[ ] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 98/ 01059

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

See continuation sheet

2. [X] Claims Nos.: 19;22 (in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Said claims relate to antagonists, inhibitors or small molecules without giving a true technical characterization of the claimed matter. In consequence, the scope of said claims is ambiguous and, moreover, their subject-matter is vague and not sufficiently disclosed.

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark: Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment). Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 4-6,8,9,12,14,20-25,27,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (applies where the subject-matter of said claims relates to an vivo treatment).
Although claim 29 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/01059

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/52 C12N9/00 A61K38/43 C07K16/40 C12N15/11
A61K48/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	BHATTTACHARYA SK ET AL: "A mammalian protein with specific demethylase activity for mCpG DNA" NATURE, vol. 397, 18 February 1999, pages 579-583, XP002097746 LONDON GB ---	
P,X	HENDRICH B ET AL: "Identification and characterization of a family of mammalian methyl-CpG binding proteins." MOLECULAR AND CELLULAR BIOLOGY, (1998 NOV) 18 (11) 6538-47. JOURNAL CODE: NGY. ISSN: 0270-7306., XP002097747 United States see the whole document ---	1-3
	-/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 March 1999	08/04/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Espen, J

2

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	SZYF M. ET AL.: "Mammalian cells contain a general (CpG) DNA demethylating activity" MOLECULAR BIOLOGY OF THE CELL, vol. 4, October 1993, page 74A XP002087767 * abstract 426 *	1
X	SZYF M ET AL: "Ras induces a general DNA demethylation activity in mouse embryonal P19 cells." J BIOL CHEM, MAY 26 1995, 270 (21) P12690-6, XP002087765 UNITED STATES see the whole document	1
X	SZYF M: "DNA methylation properties: consequences for pharmacology." TRENDS PHARMACOL SCI, JUL 1994, 15 (7) P233-8, XP002087766 ENGLAND see page 234, right-hand column; figures 1,2	1
X	WEISS A ET AL: "The role of DNA demethylation during development." GENES TO CELLS, (1997 AUG) 2 (8) 481-6. REF: 35 JOURNAL CODE: CUF. ISSN: 1356-9597., XP002097748 ENGLAND: United Kingdom see figures 3,4	1
X	WEISS A ET AL: "DNA demethylation in vitro: involvement of RNA" CELL, vol. 86, 1996, pages 709-718, XP002097749 NA US see the whole document	1
X	WO 95 15373 A (UNIV MCGILL ;SZYF MOSHE (CA)) 8 June 1995 see claims 12,13	1

2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CA 98/01059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9515373 A	08-06-1995	CA 2110213 A	31-05-1995
		AU 1061395 A	19-06-1995
		CA 2177031 A	08-06-1995
		EP 0734436 A	02-10-1996
		EP 0889122 A	07-01-1999
		JP 9506253 T	24-06-1997

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
1770-183PCT		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/CA98/01059	12/11/1998	12/11/1997
International Patent Classification (IPC) or national classification and IPC C12N15/52		
Applicant McGILL UNIVERSITY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 8 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 1 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☒ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
07/06/1999	10.02.00
Name and mailing address of the international preliminary examining authority: European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized officer Espen, J Telephone No. +31 70 340 2625

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/01059

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-44	as originally filed				

Claims, No.:

9-29	as originally filed				
1-8	as received on	09/12/1999	with letter of	09/12/1999	

Drawings, sheets:

1/36-36/36	as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 19, in part: 22; 4-6 (in part), 8,9,12,14,20-25,27,28; with respect to industrial applicability.

because:

☒ the said international application, or the said claims Nos. 4-6 (in part), 8,9,12,14,20-25,27,28 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 19, in part: 22.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Inventive step (IS)	Yes:	Claims	4-9,12-18,20,21,22,23-29
	No:	Claims	1-3,10,11
Industrial applicability (IA)	Yes:	Claims	1-3; in part: 4-6; 7,10,11,13,15-18,26,29
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item II
Priority

The present international application relates to the following priority documents:

- CA 2 220 805 (12 Nov 1997) (**prio 1**),
- CA 2 230 991 (11 May 1998) (**prio 2**).

Prio 1 relates to DNA methylase, however no corresponding sequences are disclosed.

Prio 2 relates to human demethylase cDNA and the deduced amino acid sequence (Fig. 4), however said sequence corresponds only to part of the sequences of SEQ ID NO 1 and 2 (Fig. 9) of present international application.
In fact, said deduced amino acid sequence corresponds to Fig. 8b of present international application.
Moreover, for SEQ ID Nos 3,4,5,6,7,8 no basis may be found in prio 2.

In consequence, the valid filing date of claims 1-3 is the 12 Nov 1998 (i.e. International filing date of PCT/CA98/01059), since said claims do not enjoy a valid priority right (Art. 8, PCT).
This also applies for the claims referring to or depending on said claims 2 and 3.

Re Item III
Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 4-6,8,9,12,14,20-25,27,28 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1). The present international application relates to a mammalian DNA demethylase. The corresponding DNA and amino acid sequences are given.

2.1). Reference is made to the following document:

D1: MOLECULAR AND CELLULAR BiOLOGY, vol. 18, pp. 6538-6547, November 11, 1998
D2: nucleotide accession number AF072242; 28 Oct 1998
D3: nucleotide accession number AF072243; 28 Oct 1998
D4 : nucleotide accession number AF072247, 28 Oct 1998
D5: nucleotide accession number AF072248, 28 Oct 1998

Documents D2 to D5 are not cited within the International Search Report, however they are referred within D1.

3). Apparently, the exact publishing date of D1 may be November 11, 1998. In order to avoid any ambiguity, the IPEA prefers also referring to D2 to D5 for establishing novelty and inventive step.

3.1). D1 relates to the cloning and expression of methyl-CpG binding domain (MBD) containing proteins MBD2 to MBD4. In particular, MBD2 and MBD3 were expressed in bacterial cells, and as GFP-MBD fusion proteins under the control of the cytomegalovirus promoter in mammalian cells. The DNA binding properties to methylated and non-methylated DNA of the recombinant MDB proteins are studied. However, D1 is silent with respect to any demethylase activity of said proteins.

3.2.1). SEQ ID No 1 (present application) has 100% identity in 1804 bp overlap with the sequence of D3 relating to Mus musculus methyl-CpG binding protein MBD2 mRNA (AF072243). The amino acid sequence deduced from AF072243: SPTREMBL:Q9Z2E1

being also given in D3 has 100% identity in 414 amino acid (aa) overlap with present SEQ ID No 6 (Fig. 9K).

3.2.2). SEQ ID No 3 (present application) has 100% identity in 1589 bp overlap with the sequence of D5 relating to Mus musculus methyl-CpG binding protein MBD3 mRNA (AF072248). The amino acid sequence deduced from AF072248: SPTREMBL:Q9Z2D8 being also given in D5 has 100% identity in 285 aa overlap with present SEQ ID No 8 (Fig. 9N).

3.2.3). SEQ ID No 5 (present application) has 100% identity in 1966 bp overlap with the sequence of D2 relating to Homo sapiens methyl-CpG binding protein MBD2 mRNA (AF072242). The amino acid sequence deduced from AF072242: SPTREMBLNEW:AAC68871 being also given in D2 has 100% identity in 411 aa overlap with present SEQ ID NO 2 (Fig. 9C).

3.2.4). SEQ ID No 7 (present application) has 100% identity in 2392 bp overlap with the sequence of D4 relating to Homo sapiens methyl-CpG binding protein MBD3 mRNA (AF072247). The amino acid sequence deduced from AF072247: SPTREMBL:O95983 being also given in D4 has 100% identity in 291 aa overlap with present SEQ ID NO 4 (Fig. 9F).

4.1). Having regard to the above mentions, claims 1-3,10,11, do not meet the requirements of Art. 33 (2) PCT for the following reasons:
Although D1 to D5 do not refer to any DNA demethylase activity of the described MBD proteins, the sequences encoding said MBD proteins and their deduced amino acid sequences are absolutely identical with the sequences given within SEQ ID Nos 1-8 of the present application (see above).
In consequence, the technical features given within claims 1-3 are not distinguishable from the technical features disclosed in D1-D5.
Furthermore, the DNA demethylase activity of said proteins is considered to be a functional feature relating to a property inherent of said MBD proteins.
D1 is also novelty destroying for claims 10,11, since their scope is embraced by the disclosures made in D1.

4.2). Claims 4-9,12-18,20,21, in part 22, 23-29 meet the requirements of Art. 33 (2) and

(3) since their subject-matter was neither described nor suggested in the available prior art.

5.1). For the assessment of the present claims 4-6,8,9,12,14,20-25,27,28 (in so far as the relate to *in vivo* subject-matter) on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

5.2). The industrial applicability of claims 1-3, in part: 4-6; 7,10,11,13,15-18,26,29 is acknowledged (Art. 33 (4) PCT).

Re Item VIII
Certain observations on the international application

Fig. 9A-9B (SEQ ID No:1) relate to human DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 5.
Fig. 9D-9E (SEQ ID No:3) relate to human DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 7.
Fig. 9I-9J (SEQ ID No:5) relate to mouse DNA demethylase 1 cDNA, however this sequence is contained in SEQ ID No 1.
Fig. 9L-9M (SEQ ID No:7) relate to mouse DNA demethylase 2 cDNA, however this sequence is contained in SEQ ID No 3.

Apparently, their exists an inconsistency not allowable under Art. 6 PCT.